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Abstract 
Essential hypertension, characterized by elevated blood pressure levels, is a 
primary risk factor for other cardiovascular diseases.  There has been a drastic rise in the 
amount of people who have essential hypertension; trends predict that 1.56 billion people 
worldwide will be living with essential hypertension by 2025. Anti-hypertensive drugs 
lower elevated blood pressure levels, but do not eliminate the disease itself or reverse the 
structural damage to arteries. This study aims to elucidate hypertension-induced 
endothelial cell (EC) dysfunction using a blood vessel tissue engineering approach as a 
pathology model.   
In order to characterize EC dysfunction, the FlexCell® system was used to induce 
a dynamic 140 mmHg transmural pressure onto EC monocultures and endothelial cell–
smooth muscle cell (EC-SMC) co-cultures over the course of four days; control samples 
were subjected to 120-mmHg.  Cell-matrix adhesion and cell-cell interaction were 
evaluated by EC culture studies and vasoregulation was the main focus for the EC-SMC 
co-culture studies.  Immunofluorescence and western blots were used to detect integrin 
β1, FAK, and VE-cadherin, as well as eNOS, endothelin, and angiotensin. Additionally, a 
novel bioreactor platform was developed to simulate and control hypertension values. 
Cell-seeded vascular scaffolds were mounted into a bioreactor system that induced a flow 
rate of 150 mL/min and a hypertensive pressure profile, which matched that of a femoral 
artery found in the human body.   
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Preliminary results showed that cells were able to attach and that the arterial 
structure remained intact.  However, dynamic rotational seeding should be implemented 
for future studies for better cell attachment on arteries.  This system could be tailored 
towards studying other vascular diseases, or modified to produce clinically relevant tissue 
engineered blood vessels, resistant to high blood pressure.  My project aims and 
approaches are listed below. 
Aim	  1:	  To	  elucidate	  how	  endothelial	  cell	  adhesion	  and	  functionality	  is	  affected	  when	  exposed	  to	  hypertensive	  conditions	  
Approach: Human aortic endothelial cells were seeded onto specialized BioFlex® 6-
well plates and subjected to both normotensive and hypertensive transmural pressures 
using the FlexCell® FX-5000 Compression System.  Immunocytochemistry and western 
blots were used to check for FAK, integrin β1, and VE-cadherin expression. 
Aim 2: To elucidate how EC-SMC vasoregulation is affected when exposed to 
hypertensive conditions 
Approach: Human aortic endothelial cells and human coronary artery smooth muscle 
cells were seeded onto specialized BioFlex® 6-well plates and subjected to both 
normotensive and hypertensive transmural pressures using the FlexCell® FX-5000 
Compression System.  Immunocytochemistry and western blots were used to check for 
angiotensin, endothelin, and eNOS expression. 
Aim 3: To develop a novel bioreactor pathology model for studying hypertension and 
other vascular diseases 
iv	  
Approach: Porcine carotid arteries were decellularized and placed into specialized 
vascular chambers.  Human coronary artery smooth muscle cells were seeded onto the 
lumen of the decellularized carotid arteries and the vascular chambers containing the re-
seeded arteries were incorporated into a bioreactor system capable of inducing 
hypertensive flow rates and pressure profiles.  Live-Dead and H&E stains were utilized to 
check for cell viability and ECM integrity.
v	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Chapter 1: Introduction 
1.1 Arterial Anatomy 
Arteries are comprised of three distinct layers that play individual roles in 
maintaining the structural integrity and functionality of arteries: the tunica intima, the 
tunica media, and the tunica adventitia.  These layers are depicted in Figure 1 below. 
Figure 1. The three layers of the arterial wall1 
The tunica intima or innermost layer of the artery is demarcated by a monolayer of 
endothelial cells (ECs) and a subendothelial basal lamina.  During development, ECs 
secrete and adhere to this basal layer composed of fibrillin-containing microfibrils and 
collagen fibers.  ECs also produce elastin, which contributes to the formation of the 
internal elastic lamina during development.  The tunica intima does not affect the 
mechanical properties of a normal blood vessel, but plays an integral part in certain 
pathologies like atherosclerosis, restenosis, and essential hypertension [1].  The internal 
elastic lamina mentioned above segregates the tunica intima from the adjacent layer, the 
tunica media. 
1 Image taken from Expert Reviews in Molecular Medicine© Cambridge University Press 
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The tunica media is mainly comprised of smooth muscle cells (SMCs) and elastin.  
Elastin in the media form porous sheets called lamellae.  In the space between each 
lamella, SMCs cluster together in a diagonal orientation between the tunica intima and 
tunica adventitia [1,2,3].  Elastic fibers protrude from each elastin lamella and connect to 
SMCs as well as adjacent lamellae creating a complex three-dimensional structure [1,3].  
Vascular elastin has low tensile strength, but has the ability to stretch when subjected the 
various stresses normally experienced by an artery.  Its distensibility allows arteries to 
uniformly disseminate the stress across the vessel wall and onto the stronger collagen 
fibers.  Even without SMCs, an artery will still be able to function physiologically 
indicating that an artery’s mechanical properties are holistically governed by collagen 
and elastin.  That claim is further supported by the fact that collagen and elastin make-up 
about 50% of an artery’s dry weight.  The total amount of lamellae and SMCs is linearly 
proportional to the amount of tensional forces a specific artery experiences.  For example, 
larger peripheral arteries will understandably have a thicker media, since they encounter a 
greater degree of wall tension [1].  Lastly, the tunica media plays an integral role in 
vasoregulation and in several pathologies including essential hypertension. 
 Structurally less organized when compared to the intima and media, the tunica 
adventitia or outermost layer of an artery is separated from the tunica media by the 
external elastic lamina.  This layer contains a large amount type-I collagen secreted by 
myofibroblasts.  Although the tunica adventitia plays a marginal role in the 
vasoregulation of arteries, the high concentration of collagen prevents arteries from 
bursting under high pressures and the myofibroblasts found in this layer contribute to 
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vascular remodeling both of which occur in essential hypertension [1,2]. 
The complex interactions between the cells and extracellular matrix (ECM) 
components found in the tunica intima and tunica media regulate blood pressure.  The 
following sections introduce these components and their interactions. 
1.2 Extracellular Matrix of Arteries 
 Although several ECM proteins make-up an artery, this section will only highlight 
collagen, elastin, glycosaminoglycans, and proteoglycans, since they are the key proteins 
that play a critical role in arterial mechanics during physiological and high blood pressure 
conditions. 
1.2.1 Elastin 
As mentioned earlier, elastin is known for its elasticity, which is an important 
property for many tissues like the lung, skin, and vasculature [1,4].  The human elastin 
gene contains 34 exons that promote the synthesis of elastin monomers called 
tropoelastin.  The tropoelastin secreted by cells have distinguishable hydrophobic 
sequences that alternate with lysine-containing cross-linking pattern.  With the help of 
other EC proteins, over 80% of tropoelastin’s lysine residues react to generate crosslinks 
within the same elastin molecule or with other elastin molecules.  A typical elastin 
molecule contains 15 to 20 crosslinks.  Crosslinking is the basis of elastin’s flexibility 
and lifetime durability.  Elastin expression only occurs only during development and 
drops off significantly as blood pressure rises to physiological levels.  There is little to no 
elastin synthesis in adults, which poses a problem when elastin becomes damaged during 
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the pathology of several diseases including essential hypertension [1]. 
1.2.2 Collagen  
Three polypeptide α-chains form the triple helical structure of a collagen 
molecule.  In order to preserve its helical structure, every third amino acid residue has to 
be a glycine (Gly) and each α-chain has the prototypical repeating amino acid pattern of 
Gly-X-Y where X and Y can be any amino acid, but is usually proline and 
hydroxyproline [41].  There are 17 different types of vascular collagen, but collagen I, III, 
and, V are among the most abundant [1,5,6].  Collagen I, III, and V exist as fibrils, which 
are made up of an uninterrupted triple helix about 300 nm long and 1.5 nm in diameter 
with short extrahelical telopeptides capping each end.  The telopeptide units do not 
exhibit the Gly-X-Y repeating sequence and are important for fibril formation [41].  More 
information on the role of the three abundant collagen types in vascular tissue will be 
introduced next. 
Collagen V is responsible for collagen fibril nucleation.  Without type V collagen, 
collagen molecules would be unable to form fibrils.  Mutations to collagen V would 
equate to decreased arterial stiffness and breaking strength, but is not as detrimental as 
mutations that hinder collagen type I and III formation [1,8]. 
Collagen types I and III serve to strengthen the vascular wall and vary in 
compartmentalization depending on the type of artery.  For example, the ascending aorta 
contains both collagen I and III in its media and adventitia.  In contrast, the thoracic aorta 
and other muscular arteries have contain mainly collagen I in their media and collagen III 
in their adventitia.  Regardless of distribution, humans would be susceptible to vessel 
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rupture if collagen I and III genes were mutated and repressed during development.  
Thus, collagen is important ECM protein for arterial integrity and functionality.  
Additionally, collagen participates in the pathology of essential hypertension [1,9,10].   
1.2.3 Glycosaminoglycans 
 Glycosaminoglycans (GAGs) can be divided into three main classes based on 
composition.  The GAGs chondroitin sulfate and dermatan sulfate fall into the first 
category.  Both have repeating disaccharide units of galactosamine and either glucuronic 
acid or iduronic acid.  The second category includes heparin and heparin sulfate, which 
contain disaccharide repeat units of glucosamine and either glucuronic acid or iduronic 
acid.  Lastly, keratin sulfate makes up the last category and is comprised of glucosamine 
and galactose dissacharide repeat units.  These GAGs bind to the protein core of 
proteoglycans via O-glycosidic linkages.  Under physiological pH levels, GAGs 
characteristically exhibit one to three negative charges per disaccharide attributed to their 
carboxylate and sulfate groups [1]. 
1.2.4 Proteoglycans 
 Proteoglycans are multidomain proteins that attach to GAGs mentioned 
previously.  The most abundant proteoglycans in blood vessels fall into two categories: 
large proteoglycans that interact with hyaluronan and small leucine-rich proteoglycans.   
In the ECM, large proteoglycans react with hyaluronic acid to create a complex, 
connected polymeric network.  Hyaluronic acid or hyaluronan consists of repeating 
disaccharide units of glucuronic acid and N-acetylglucosamine forming a linear polymer.  
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Hyaluronan is created on the plasma membrane of cells through three types of 
hyaluronan synthases: HAS1, HAS2, and HAS3.  Mature hyaluronan stays attached to 
the cell surface by its synthase enzyme or by cell surface receptors like CD44 or 
RHAMM [11,12,13]. 
 The largest proteoglycan found in blood vessels is called versican located in the 
aortic media and endothelial layers.  Versican attached to chondroitin sulfate functions to 
promote cell adhesion, proliferation, and cell migration [14,15,16].  Compared to 
versican, aggrecan, another large aggregating proteoglycan, has a smaller protein core, 
but contains three times the amount of GAGs.  This proteoglycan has a lower abundance 
in blood vessels and is sequestered to the outer layers of the aortic wall.  The function of 
aggrecan remains unknown [14]. 
 Small leucine-rich proteoglycans are also secreted by cells except they bind to 
other ECM molecules (i.e. collagen, tropoelastin, and fibronectin) instead of hyaluronan.  
Decorin, biglycan, and lumican fall into this category of proteoglycans.  Both biglycan 
and decorin attach to collagen and regulate collagen fibril formation.  Biglycan can be 
found in all layers of the human aorta, but decorin is seen only in the adventitia of the 
human aorta.  Lastly, lumican is found in the medial and adventitial layers of 
nonatherosclerotic human coronary arteries and also influences collagen fibril formation.  
The next section will describe the three cell types found in vasculature: endothelial cells, 
smooth muscle cells, and fibroblasts [1]. 
1.3 Cells of Arteries 
 The three primary cell types found in arteries are endothelial cells, smooth muscle 
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cells, and fibroblasts.  These cells are essential for physiological arterial structure and 
function.  Each cell type will be discussed in-depth in this section. 
1.3.1 Endothelial Cells 
There are between 1*1013 and 6*1013 endothelial cells (ECs) in an adult human 
that make up the endothelium and overlays a total vascular surface area between 1 and 7 
m2.  ECs are a part of several physiological pathways within the body such as 
vasoregulation, angiogenesis, and immune response [17,18].  They also play a role in 
several pathologies including hypertension, which will be examined in the pathology 
section. 
With the advent of advanced genetic engineering techniques, scientists have 
determined that the cardiovascular system is the first to form during gastrulation.  The 
embryo organizes ECs into new blood vessels, a process regarded as vasculogenesis.  
Once the primary vascular framework is established, angiogenesis takes over where ECs 
spawn off of pre-existing blood vessels creating the complex human vascular network.  
Angiogenesis serves as the primary mode of vessel formation during human development 
and in mature adults where it is seen predominantly in wound healing and tumor 
metastasis [17,19]. 
 Nascent blood cells form in the yolk of the embryo lead to the simultaneous 
formation of vascular and hematopoietic tissue.  Angioblasts, which eventually gives rise 
to the outer layer of ECs, encapsulate nascent blood cells and hematopoietic stem cells 
ultimately fostering the development of mature blood cells.  Angioblasts stem from the 
lateral mesoderm plate and cardiac crescent.  Angioblasts either migrate to the brain or 
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form the base of the heart tube allowing circulation to ensue throughout the growing 
embryo.  With directional stimuli from the endoderm, vasculogenesis ensues and forms 
the vasculature of major organs within the body [17,20,21,22].   
Upon maturity, ECs that line arteries orient themselves in the direction of blood 
flow due to hemodynamic shear stress.  The mature endothelium is a complex membrane 
that is regulated by receptors bound to endothelial cells, which can interact with 
molecules flowing in the blood stream (i.e. proteins, lipids, and metabolic molecules).  
However, it is important to understand that ECs can assume different phenotypes 
depending on the type of organ, the type of blood vessel, and location in the body [23].  
ECs are the first to respond to environmental cues, but SMCs receive and create the 
physiological response to the signaling molecules secreted by ECs in order to elicit 
vasoregulation. 
1.3.2 Smooth Muscle Cells 
Smooth muscle cells (SMCs) are also essential for the maintenance and 
functionality of blood vessels.  They have the ability to control the vascular tone of a 
blood vessel by responding to specific signaling molecules such as nitric oxide, 
endothelin-1, and angiotensin-II [24,25,26].  As a result, SMCs impact blood flow and 
blood pressure. 
After ECs form a tube-like structure resembling a vessel wall and blood flow 
starts, vascular SMCs migrate from surrounding mesenchyme and/or from the cardiac 
neural crest to start adding to the vessel wall [1,27,28].  The angiopoietin/Tie receptor 
pathway plays a significant role in SMC differentiation, but other factors that contribute 
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to SMC differentiation remain unknown [28,29].  Furthermore, different vessels have 
their own unique set of SMCs that were derived from specific sources of progenitor cells.  
For large elastic arteries, four types of precursor cells give rise to SMCs: 1) secondary 
heart field precursors differentiate into SMCs found in the aorta’s base and pulmonary 
trunk; 2) cranial neural crest cells give rise to SMCs in the ascending aorta, the ductus 
arteriosus, the innominate and right subclavian arteries, and the right and left common 
carotid arteries; 3) somatic and 4) splanchnic mesoderm precursors differentiate into 
SMCs found in the dorsal aorta [1,30].  Furthermore, there is growing evidence that fetal 
or adult endothelial cells, macrophages, and marrow-derived progenitor cells can 
transdifferentiate into SMCs [31,32,33,34,35].  No matter the origin, SMCs exhibit a high 
level of plasticity throughout development and adulthood. 
 Due to their diverse functionality, SMCs can assume a spectrum of different 
phenotypes ranging from contractile to synthetic [24,25,36].  The two distinct SMC 
phenotypes are illustrated in Figure 2 below. 
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Figure 2. Contractile vs. Synthetic SMCs2 
Aside from morphology, contractile SMCs contain more intracellular filaments that aid in 
contraction, whereas synthetic SMCs contain organelles (i.e. the rough endoplasmic 
reticulum, the Golgi apparatus, and ribosomes) that are necessary for synthesizing 
proteins that form the ECM [25].  During vasculogenesis, they are more synthetic in 
order to proliferate and secrete important ECM components that comprise the vessel wall.  
However, in mature vasculature, SMCs are more contractile and are tailored for 
vasoregulation [24,37].  Although contractile SMCs predominate in mature vasculature, 
vascular SMCs can quickly alter their phenotype in response to certain environmental 
conditions.  For example, vascular SMCs are highly proliferative in hypertensive patients 
and animals [25,38,39]. 
Since the contractile phenotype is commonly found in vascular arteries, 
contractile SMCs are desired for tissue engineering applications, but maintaining the 
contractile SMC phenotype proves to be the greatest challenge when culturing SMCs in 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 Image taken from Beamish, J. A., He, P., Kottke-Marchant, K., & Marchant, R. E. (2010). Molecular Regulation of 
Contractile Smooth Muscle Cell Phenotype: Implications for Vascular Tissue Engineering. Tissue Engineering Part B: 
Reviews, 16(5), 467-491. doi:10.1089/ten.teb.2009.0630 
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vitro.  Signaling molecules such as platelet-derived growth factors (PDGF), fibroblast 
growth factors (FGFs), insulin-like growth factors (IGFs), epidermal growth factors, α-
thrombin, factor Xa, entothelin-1, and unsaturated lysophosphatidic acids cause SMCs to 
take on a more synthetic phenotype allowing them to increase their proliferation rates.  
For in vitro SMC cultures, fetal bovine serum is commonly added to media in order to 
maintain the more synthetic and proliferative SMC phenotype.  However, signaling 
molecules such as heparin, transforming growth factor beta 1 (TGF-β1), angiotensin-II, 
and IGF-1 can be used to revert synthetic SMCs back to a more contractile phenotype 
[24]. 
In conclusion, ECs and SMCs work together to promote vasoregulation.  The 
bioactive molecules and signaling pathways that govern the crosstalk between ECs and 
SMCs will be introduced in the next section. 
1.3.3 ECs and SMCs in Vasoregulation 
ECs are responsible for controlling blood flow and pressure by modulating the 
vascular tone of blood vessels.  Vascular constriction or dilation is highly dependent on 
the concentration of bioactive substances or molecules present in the blood stream.  Upon 
detection, paracrine signaling allows one EC to communicate with neighboring ECs 
promoting the appropriate EC response.  ECs secrete nitric oxide (NO) and prostacyclcin 
(PGI2) to induce vasodilation or endothelin (ET) and platelet-activating factor (PAF) to 
cause vasoconstriction.  These molecules are not harbored by ECs, but are a product of 
either cellular metabolism or genetic transcription [17]. 
NO is a heterodiatomic free-radical created from the oxidation of L-arginine to L-
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citrulline via endothelial nitric oxide synthases (eNOS) embedded in the plasma 
membranes of ECs [17].  eNOS is always active in ECs, but receptor-dependent agonists 
such as thrombin, adenosine 5’ -diphosphate, bradykinin, substance P, and muscarinic 
agonists coupled with abnormal shear stress and cyclic strain elevate eNOS activity.  
These agonists and environmental cues open calcium trans-membrane ion-channels that 
lead to an influx of calcium molecules, which in turn activates eNOS.  When NO 
production is complete, ECs secrete NO onto underlying SMCs activating the guanylate 
cyclase pathway where GTP is converted to cGMP; this causes SMCs relaxation and 
ultimately vessel dilation.  This whole process is termed endothelium-dependent 
vasodilation shown in Figure 3 below: 
 
Figure 3. Endothelium Dependent Vasodilation3 
This is the pathway that is primarily responsible for alleviating hypertension, but can be 
compromised during prolonged exposure to high blood pressure conditions [41].  More 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3 Image taken from Gornik, H. L., & Creager, M. A. (2004). Arginine and Endothelial and Vascular Health. The 
Journal of Nutrition, 2880-2887. 
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detail on the pathological alteration of the NO pathway will be introduced in section 
1.6.1.  Additionally, NO secreted by ECs work with PGI2 to inhibit platelet activation and 
adhesion.  NO also prevents leukocyte adhesion onto the endothelium and downplays the 
proliferation and migration of SMCs.  Lastly, its interaction with SMCs is important 
during wound healing, tissue regeneration, and the inhibition of neointimal hyperplasia 
[17,41]. 
ECs also produce ET, which serves as a potent vasoconstrictor [17,42]. 
Preproendothelin-1, the precursor to endothelin, is produced within ECs.  Hypoxia, 
ischemia, and abnormal shear stress convert preproendothelin-1 to normal ET-1.  ECs 
secrete ET-1 proteins where they eventually bind to G-protein-coupled ET-A receptors 
found on SMCs.  This ligand-receptor interaction raises the intracellular calcium within 
SMCs causing them to constrict the blood vessel.  The effect on intracellular calcium is 
prolonged even after ET-1 detaches from the receptor, which is why NO is needed to 
counteract ET-1 and return the calcium levels back to normal in SMCs [17,42,43]. 
Secondary bioactive molecules, PGI2 and PAF, also affect the adhesion of cells in 
the bloodstream and complements NO and ET by assisting vasoregulation.  PGI2, an 
eicosanoid, and PAF, a phospholipid, are not typically found in a resting EC and are 
synthesized within ECs in response to humoral immunity and mechanical stresses.  Upon 
synthesis, these molecules are ephemeral, which limits the range of their effects [17].   
The key differences between PGI2 and PAF lie in their signaling pathway where 
PGI2 is a paracrine signaling ligand and PAF is a juxtacrine signaling ligand.  PGI2 is 
released into the bloodstream and binds to prostacyclin (IP) receptors.  These type of 
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receptors are found on platelets in circulation thwarting their adhesion and aggregation.  
IP receptors are also found on vascular smooth muscle cells and serves as a localized 
smooth muscle relaxer causing localized vasodilation.  Although IP receptors are always 
present on both platelets and smooth muscle cells, it is important to reiterate the fact that 
PGI2 molecules are not present in quiescent ECs, but is, rather, synthesized under 
irregular vascular conditions [17,44]. 
  Antithetically, PAF is travels from within the EC and becomes expressed onto 
the cell’s surface similar to G-protein linked receptors.  The PAF membrane ligand binds 
to its receptors on leukocytes causing leukocytes to adhere to the endothelium.  
Additionally, PAF molecules serve as either a vasoconstrictor or vasodilator depending 
on the concentration of PAF ligands expressed on the surface of ECs, the longevity of the 
signal, and the specific region of vasculature.  Similar to PGI2, PAF is not expressed 
under normal conditions [17,46]. 
1.3.4 Fibroblasts 
Although they do not directly influence blood pressure levels, fibroblasts play a 
part in both physiological and pathological vascular remodeling in response to blood 
pressure conditions.  Fibroblasts are stromal cells that serve to secrete essential ECM 
components.  Similar to ECs and SMCs, they display heterogeneity [46]. 
Fibroblasts can vary in smooth muscle α-actin concentration, morphology, and 
types of adhesive structures.  Under the right mechanical stimuli, activated fibroblasts or 
myofibroblasts express more SM α-actin as well as form cytoplasmic microfilamentous 
system, fibronexus junctions, and other characteristics similar to SMCs [46,47].  EC 
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damage activates SMCs and fibroblasts leading to the following cascade of cellular 
events: 1) apoptosis and cell proliferation, 2) ECM production, 3) appearance of SM-like 
cells and alterations to SMCs, 4) migration of adventitial fibroblasts, and 5) adventitial 
scarring. 
Although vascular remodeling led by fibroblasts is normal, severe vascular injury 
converts normal fibroblasts into myofibroblasts, which synthesize and deposit more 
ECM.  This phenomenon coupled with hyperplasia leads to unwarranted neointima 
formation and adverse vascular remodeling commonly associated with vascular diseases 
[48]. 
1.4 Arterial Physiology 
The vascular endothelium experiences different types of mechanical forces due to 
blood flow, blood pressure, and the forces exhibited by surrounding tissues.  Radial 
forces associated with blood pressure act directly on the endothelium and cause arteries 
to distend.  Reactionary forces exerted by SMCs in the tunica media and surrounding 
tissue prevent blood vessels from bursting by counteracting a majority of the distending 
forces.  Transmural pressure refers to the resulting net radial forces acting on the arterial 
wall.  Transmural pressure defines the steady state of the blood vessel by affecting vessel 
diameter and flow rate.  At the cellular level, transmural pressure affects EC height, 
shape, and ultimately functionality [49].   
 The distensibility and elasticity of blood vessels caused by the transmural 
pressure engenders circumferential and longitudinal forces, respectively.  LaPlace’s Law 
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can define the circumferential force component, also known as hoop stress (T): 𝑇 = !!∗!!!  
where ΔP represents transmural pressure, r represents the radius of the blood vessel, and t 
represents time.  Like blood pressure, the wall strain varies with time throughout the 
cardiac cycle.  For my thesis, wall strain will be treated as a uniaxial waveform in the 
circumferential direction.  Both circumferential and longitudinal forces play a role in 
artery development and remodeling. 
 The last type of force experienced by the endothelium is shear force caused by the 
flow of blood through the vessels.  Under normal conditions, the flow of blood can be 
perceived to be laminar, which means that the flow profile of blood can be divided into 
different fluid layers sliding past one another.  Additionally, the shear rate or the change 
in fluid speed parallel to the vessel wall with respect to each fluid layer is obtainable.  
Treating blood as a Newtonian fluid with constant viscosity (µ) is acceptable if blood is 
flowing through large blood vessels.  For a Newtonian fluid, the shear stress or the force 
one layer exerts on an adjacent layer is directly proportional to the shear rate and can be 
represented by the following equation: 𝜏 = 𝜇𝛾.  Additionally, if the flow is laminar and 
the diameter of the blood vessel is constant, the vessel wall shear stress caused by blood 
flow can be correlated to volumetric flow rate (Q) using the following equation: 𝜏!"## = !!"!!! .  Since the artery walls experience pulsatile forces due to the varying blood 
pressure levels throughout the cardiac cycle, the wall shear stress also varies spatially and 
temporally, which is essential for proper endothelial functionality. All the forces that act 
on the wall of a blood vessel are depicted in Figure 4. 
	  	   17	  
 
Figure 4. Forces acting on a blood vessel wall4 
1.4.1 Endothelial Mechanosensing 
 The various mechanical forces experienced by ECs vary depending on the focal 
points they act on during specific time points; this spatial and temporal heterogeneity 
institutes the physiological condition, but can also provoke EC dysfunction associated 
with vascular disease.  For instance, blood vessels that are normally subjected to high 
pulsatile shear stresses use this mechanical stimuli to up-regulate genes and induce 
signaling pathways needed for protection.  However, with regards to disease, 
atherosclerotic plaque and EC dysfunction are commonly present at bifurcations or 
sections of high curvature on large arteries because of the intricate flow profiles 
experienced in these areas [49].  The localized forces at these regions leads to an 
inflammatory response.  Thus, mechanical forces dictate proper or aberrant EC 
functionality through mechanotransduction or the conversion of mechanical stimuli into 
cellular responses via intracellular signaling pathways. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4 Image taken from Aranda-Espinoza, H. (n.d.). Mechanobiology of the endothelium. 
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1.4.2 Cytoskeletal Mechanotransduction 
 The cytoskeleton of an EC is critical for vascular adaptation to stretch and shear 
forces.  Intracellular microfilaments, intermediate filaments, and microtubules uphold the 
morphology of an EC, but also facilitate cellular remodeling via mechanotransduction.  
For example, unidirectional shear stress and cyclic stretch lead to actin turnover and 
reorganization, which lead EC alignment.  Cytoskeletal mechanotransduction occur at 
two adhesion sites: cell-matrix and cell-cell contacts; the mechanosensory proteins found 
at focal adhesions or cell-matrix contacts and adherens junctions or cell-cell contacts 
dictate the proper cellular response to mechanical forces.  Vessel wall stretching, for 
instance, felt by integrins on the luminal surface of ECs is directly transferred to the 
underlying focal adhesion proteins, but also indirectly impacts adherens junction proteins.  
For this to occur, the actin cytoskeleton serves as the primary connector between the two 
types of proteins.  If the actin cytoskeleton is damaged, mechanotransmission is 
incomplete leading to EC dysfunction [49].  Three important adhesion proteins, integrins, 
FAK, and VE-cadherin, aid in mechanotransduction will be examined in the following 
sections. 
1.4.3 Integrins 
 Integrins are found within focal adhesion sites and serve to link the ECM to the 
intracellular cytoskeleton.  Various mechanical stimuli induce conformational changes in 
both domains of this transmembrane protein.  They persist in either an inactive, low-
affinity conformation or an active, high-affinity conformation; conformational switching 
between the two types induces specific cell responses.  “Inside-out activation” occurs 
	  	   19	  
when interactions in the intracellular domain of the integrin causes changes in its 
extracellular domain.  Conversely, “outside-in activation” occurs when ligands bind to 
active, high-affinity integrin, which induce a conformational change that lead to 
downstream intracellular signal transduction.  Integrin activation based on affinity to 
certain ligands inevitably leads to integrin clustering at specific regions on ECs.  These 
regions are referred to as focal adhesions and vary by the types of scaffolding and 
signaling proteins (i.e. FAK, Src, paxillin, and vinculin) recruited to these areas, so focal 
adhesions are quintessential for shear-stress induced mechanotransduction [49]. 
1.4.4 Focal Adhesion Kinase 
Focal adhesion kinase (FAK) is an intracellular protein that is bound to the 
intracellular domain of integrin β1 and is associated with the complex intracellular actin 
filament network as seen below [50]. 
 
Figure 5. Integrin β1 and FAK association5 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
5 Image taken from Zebda, N., Dubrovskyi, O., & Birukov, K. G. (2012). Focal Adhesion Kinase Regulation of 
Mechanotransduction and its Impact on Endothelial Cell Functions. Microvascular Research, 83(1), 71-81. 
doi:10.1016/j.mvr.2011.06.007 
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As stated before, this molecule responds to mechanical stimuli that induce several 
signaling pathways that regulate EC adhesion and functionality, which ultimately affects 
EC barrier functionality, monolayer formation, and a variety of several other cell 
processes like cell migration, proliferation, apoptosis, and adhesion [50]. 
FAK regulates cell adhesion by interacting directly and inadvertently with actin 
and adhesion proteins like RhoGTPases.  Neural Wiskott-Aldrich syndrome protein (n-
WASP) influences RhoGTPases and serves as a binding site for FAK.  WASP translates 
extracellular mechanical stimuli to cytoskeletal remorganization by regulating actin-
related protein (Arp 2/3).  Upon phosphorylation, transcription factors associated to 
WASP instigate cell migration.  WASP phosphorylation activates FAK causing a 
conformational change in Arp2/3, since FAK is linked to Arp2/3 at its N-terminus.  Now, 
actin monomers are recruited to the Arp2/3 and polymerized.  Arp2/3 is attached to 
integrins at focal adhesion sites, so the FAK-Arp interaction is the first step in the 
transduction of a mechanical stimuli to a cellular response.  Additionally, α-catenin This 
signaling pathway ultimately preserves EC adhesion and structure.  Furthermore, FAK 
transfers the mechanical stimuli experienced by integrins in focal adhesions to adherens 
junctions [51]. 
1.4.5 Adherens Junctions – VE-cadherin 
 As introduced in the previous section, adherens junctions respond to the shear 
stress encountered by ECs.  Figure 6 below shows the basic structure of an adherens 
junction centralized around the transmembrane glycoprotein, VE-cadherin or cadherin-5. 
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Figure 6. Multiple intracellular and intercellular transduction pathways linked to an adherens junction6 
Classical cadherins are the responsible for regulating calcium dependent cell-cell 
adhesion.  They are divided into subtypes I and II depending on sequence homology.  
VE-cadherin is a type-II endothelial restricted classical cadherin because only 23% of its 
sequence is identical to the two other type-I classical cadherins, epithelial and neuronal, 
which will be excluded from this section due to the scope of this project [52].  In this 
case, VE-cadherin has an extracellular domain that exclusively attaches to the 
extracellular domain of the VE-cadherin on the neighboring EC forming a homodimer.  
The bond between the two extracellular domains of adjacent VE-cadherins is weak by 
itself, but the numerous clusters of VE-cadherins between ECs greatly strengthen 
endothelial cell-cell adhesion.  The C-terminus of VE-cadherin’s intracellular domain is 
bound to p120-catenin and β-catenin or plakoglobin, which are connected to the actin 
cytoskeleton.  Subsequently, β-catenin is bound to the N-terminus of α-catenin.  Studies 
have shown that α-catenin can bind to both β-catenin and the actin cytoskeleton, but not 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
6 Image taken from Quadri, S. K. (2012). Cross talk between focal adhesion kinase and cadherins: Role in regulating 
endothelial barrier function. Microvascular Research, 83(1), 3-11. doi:10.1016/j.mvr.2011.08.001 
	  	   22	  
at the same time.  Conflicting results from previous studies have refuted the idea that α-
catenin affects cell adhesion and the functionality of the actin-catenin-cadherin complex.  
The complexity of actin-catenin-cadherin interactions with regards to cell-cell adhesion 
and the EC barrier in response to mechanical stimuli remains unclear and is an ongoing 
research topic.  The figure also shows that VE-cadherin is linked to several signaling 
pathways and can regulate many different cell responses like adhesion, migration, 
proliferation, apoptosis, and differentiation [51,52]. 
Since cadherins are structural proteins that are not inherently active, their role in 
signal transduction relies heavily on its physical interactions with surrounding molecules 
and depends on environmental conditions.  Once the endothelial monolayer is established 
in mature vessels, VE-cadherins are indirectly involved in pathways that uphold vascular 
integrity by halting proliferation and growth, prohibiting against apoptosis, and 
monitoring vascular permeability.  Under abnormal environment conditions like high 
blood pressure, adherens junctions between cells open, thereby compromising signal 
transduction.  This results in EC dysfunction, which is associated with several vascular 
diseases and conditions such as hypertension, diabetes, and atherosclerosis [51].  The 
cross-talk between VE-cadherin and focal adhesion kinase will be explored further. 
1.4.6 Cross-talk between FAK and VE-cadherin 
FAK and VE-cadherin expression determine the adhesive properties and signaling 
capabilities of the ECs.  These specific signaling pathways can cause a cell-specific 
response to its environment (i.e. blood pressure, flow, and pulsatility).  Although FAK 
does not directly bind to VE-cadherin, it indirectly influences the activity of the adherens 
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junction through intermediate molecules.  The pathway that links the FAK and VE-
cadherin can be seen in Figure 7 below. 
 
Figure 7. Pathways in which FAK influences VE-cadherin7 
As seen in the diagram, FAK does not bind directly to β-catenin, but sends signals to 
Rho-family GTPases Rac1 and CDC42.  These signals cause the GTPase-activating 
protein IQGAP1 to bind to Rac1 and CDC42 instead of β-catenin conserving the bond 
between the cadherin complex and the cytoskeleton.  Without FAK mediation, free form 
IQGAP1 would naturally bind β-catenin and dislodge α-catenin consequently severing 
the link between the cadherin complex and the cytoskeleton.  Additionally, p120-catenin 
also serves to activate Rac1 and CDC42 using VAV2 via a mechanism that is still 
unclear.  Hence, the FAK-cadherin crosstalk is essential for conserving EC cell-matrix 
and cell-cell adhesion as well as physiological EC functionality [51].  However, 
hypertension can disrupt cell-cell adhesion and induce EC dysfunction. 
1.5 Background – Hypertension 
 Essential hypertension or primary hypertension is defined as elevated blood 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
7 Image taken from Quadri, S. K. (2012). Cross talk between focal adhesion kinase and cadherins: Role in regulating 
endothelial barrier function. Microvascular Research, 83(1), 3-11. doi:10.1016/j.mvr.2011.08.001 
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pressure levels that do not stem from other diseases such as diabetes mellitus or kidney 
disease, but this form of hypertension is the primary risk factor for other cardiovascular 
diseases.  A patient is diagnosed with essential hypertension if their systolic blood 
pressure is ≥140 mmHg and their diastolic pressure is ≥90 mmHg.  The National Health 
and Nutrition Examination Survey (NHNES) has remained the primary predictor for the 
prevalence of hypertension in the United States from 1960 to 2002.  Between 1960 and 
1962, hypertension prevalence was at 29.7% and increased to 36.3% between 1971 and 
1974.  With the advancement of technology and improvement in hospital care, the 
prevalence of hypertension in the United States dropped to 31.8% from 1976 to 1980 and 
then to a steady 25% from 1988-1994.  However, hypertension prevalence climbed back 
up to 28.6% between 1999 and 2002 and will continue to rise in the upcoming years, not 
only in the United States, but worldwide.  Current trends estimate that 1.56 billion people 
worldwide will be living with hypertension by the year 2025.  This increase in prevalence 
can be attributed to growing aging populations and the development of countries around 
the world.  People are living longer because of improved healthcare and technology, but 
aging is associated with complications such as hypertension.  People living in developing 
countries are exposed to more dietary contributors of high blood pressure such as an 
increased consumption of salt, calories, and alcohol.  High blood pressure can be reduced 
by a change in diet and can be controlled using drugs.  Although current pharmacological 
therapies can normalize a patient’s blood pressure, they cannot reverse the damage to 
arteries and associated cells.  Autologous veins and synthetic grafts can be used to 
replace damaged arteries, but complications arise in patients who do not have healthy 
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veins for transplantation and synthetic grafts have issues with thrombogenicity due to the 
lack of endothelialization [53]. 
1.6 Pathophysiology 
It is important to understand the pathophysiology of large arteries when subject to 
hypertension.  Hypertension engenders two adverse events in large arteries: EC 
dysfunction and vascular remodeling. 
1.6.1 Endothelial Cell Dysfunction 
EC dysfunction describes the functional and reversible phenotypic change in ECs 
that circumscribes NO availability.  The amount of vasodilation an artery experiences in 
response to pharmacologic or mechanical stimuli determines the degree of EC 
dysfunction.  This vasodilatory effect relies heavily on NO production, which is a 
bioactive molecule that regulates endothelial cell functionality.  Excessive vascular 
oxidative stress and inflammation contribute to reduced levels of NO resulting in EC 
dysfunction [54,55].   
Reactive oxygen species (ROS), predominantly superoxide anions, degrade NO-
producing peroxynitrates resulting in impaired endothelial structure and function.  
Several enzymatic and nonenzymatic proteins like xanthine oxidase and cyclooxygenase 
can produce these oxygen-free radicals.  Furthermore, cofactor tetrahydrobiopterin (BH4) 
reduction and NADPH-oxidase activity sponsor the production of superoxide species 
[55].  A study where mice carotid arteries were subjected to increasing luminal pressures 
showed that systemic oxidative stress occurs because of amplified vascular superoxide 
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production by the mitochondria of ECs, increased activity of NADPH oxidases, and 
decreased response to acetylcholine induced vasodilation.  Studies that down-regulated 
Rac-1 using small interfering RNA (siRNA) caused integrin-kinase 1 to be 
overexpressed, which is the first step in the mechanotransduction pathway that leads to 
vascular superoxide production via NADPH oxidase in reaction to elevated blood 
pressure levels [54].  Another study determined whether a patient had NO impairment by 
observing a hypertensive patient’s response to NG-monomethyl-L-arginine (L-NMMA) 
infusions, a NO inhibitor.  Patients exhibiting a diminished vasodilatory response to the 
presence of L-NMMA correlated to NO impairment.  The reduction in oxidative end 
products of NO, plasma nitrite and nitrate, found in patients with essential hypertension 
was also a strong indicator of compromised NO production [55].  The mechanisms 
behind the release of hypertension-induced ROS has been validated for cyclooxygenase, 
proven unrelated to xanthine oxidase, and needs to be further investigated in relation to 
NADPH oxidases.  However, the release of ROS due to high blood pressure can be 
conclusively accepted as a paradigm that yields endothelial cell dysfunction [54].  The 
second contributor to endothelial cell dysfunction is the inflammatory response related to 
hypertension. 
 Researchers and clinicians have discovered that inflammatory and anti-
inflammatory adipokines found in adipose tissue play an important role in metabolism 
and inflammation.  Recent studies have shown the effect of high blood pressure on the 
role of perivascular adipose tissue in maintaining homeostasis.  The adipose tissue from 
hypertensive rats could not prevent induced vasoconstriction when exposed to 
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phenylephrine (a vasoconstrictor), whereas normotensive rats could.  These studies link 
the role of perivascular adipose tissue to hypertension-induced inflammation, but future 
studies must be conducted to elucidate the exact mechanisms behind the finding.  The 
innate and adaptive immune response also affects endothelial cell functionality when 
under high blood pressure conditions.   
The complement pathway activation of the innate immune response can 
negatively impact EC functionality.  On the other hand, the over-expression of anti-
inflammatory interleukin-10 from the adaptive immune system stymies angiotensin II-
associated hypertension.  Additionally, diminished levels of endothelial progenitor cells 
(EPCs) in circulation indicate endothelial dysfunction.  These cells from the myeloid 
pluripoetent stem cell lineage can differentiate into mononuclear cells involved in 
immunity.  They also play an important part in preserving vascular homeostasis due 
largely in part to their regenerative and reparative capabilities.  However, hypertension 
enervates the regeneration and reparation ability of EPCs in humans [54].  The activation 
of complement fragment C3a also aids in the depletion of EPCs in circulation.  Thus, the 
degree of endothelial dysfunction relies heavily on the activation and presence of C3.  All 
of these findings link endothelial dysfunction to both local and systemic hypertension as 
well as the production of reactive oxygen species, which is represented by Figure 8 
below. 
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Figure 8. Synergism between Hypertension and EC Dysfunction8 
A strong correlation between hypertension and endothelial dysfunction was garnered over 
the years.  The Farmingham offspring cohort determined that elevated levels of blood 
pressure lead to a greater degree of EC dysfunction.  Although the relationship between 
hypertension and endothelial dysfunction is established, researchers do not fundamentally 
understand whether EC dysfunction prompts or stems from hypertension.  A study where 
eNOS was deliberately inhibited led to endothelial dysfunction and the subsequent 
development of hypertension in their subjects.  Another study proved that women with 
endothelial dysfunction exhibited a significant increase in the risk of developing 
hypertension.  Both studies support the idea endothelial dysfunction preceded 
hypertension.  Despite these findings, conflicting results from other studies prevaricates 
the relationship between endothelial dysfunction and hypertension.  For example, a report 
revealed that sudden, drastic elevations in blood pressure of healthy young men hindered 
endothelial functionality seen by the increase of blood flow in the brachial artery, also 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
8 Image taken from Dharmashankar, K., & Widlansky, M. E. (2010). Vascular Endothelial Function and Hypertension: 
Insights and Directions. Curr Hypertens Rep Current Hypertension Reports, 12(6), 448-455. doi:10.1007/s11906-010-
0150-2 
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known as flow-mediated dilation (FMD) [54].  Another study implicated that early onset 
of hypertension in adolescence leads to eventual endothelial dysfunction in adulthood.  
Shimbo and his contemporaries created the largest study addressing this controversy by 
sampling 3500 ethnically diverse who were a part of Multiethnic Study of 
Atherosclerosis to see if flow-mediated dilation caused by endothelial dysfunction was a 
substantial factor in the development of hypertension.  The study maintained the idea that 
endothelial dysfunction is a product of hypertension.  Regardless of the ambiguity in the 
relationship between endothelial dysfunction and hypertension, it is a problem to normal 
vascular physiology.  This thesis will present studies that hopefully elucidate this 
controversy further [54,55]. 
1.6.2 Deterioration of the NO Pathway and NO Interactions 
 Vasoconstrictors, angiotensin II and endothelin-1 (ET-1), can interact with the 
NO signaling pathway exacerbating the progression of hypertension-induced endothelial 
dysfunction.  Research evidence illustrates that although ET-1 levels remain constant in 
plasma of patients with essential hypertension, ET-1 activity becomes up-regulated in 
conjunction with reduced NO levels.  NO typically inhibits the activation of endothelin 
type-B receptors thereby hindering ET-1 production and activity, but this inhibitory 
quality of NO becomes undone in patients with essential hypertension due to lower levels 
of NO.  For patients with essential hypertension, the balance between NO and ET-1 shifts 
in favor of ET-1.  Additionally, angiotensin II can either promote or impair endothelial 
functionality.  Angiotensin II can lead to the destruction of NO if its AT1 receptor sites 
are activated causing increased NADPH oxidase activity.  Conversely, angiotensin II can 
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also stimulate NO production in ECs if its AT2 receptors are activated [55].  The role 
angiotensin II plays in hypertension pathology needs to be further elucidated.  Since there 
are several pathways and interactions that cause EC dysfunction, numerous 
antihypertensive drugs are used to combat essential hypertension and reverse endothelial 
dysfunction, discussed in-depth in the treatment section. 
1.6.3 Indicators of EC Dysfunction and Hypertension 
 Patients with essential hypertension exhibit an attenuated response to 
acetylcholine when injected into their forearm.  This aberrant reaction indicates that the 
patient’s vasculature is undergoing intima-media thickening of their carotid arteries, 
which is typically a sign of atherosclerosis.  Further supporting this relationship, the 
epicardial coronary arteries of normotensive patients examined using intravascular 
ultrasound showed a response to acetylcholine that is the inverse to the patients with 
hypertension-induced intima-media thickening.  These results have shown that EC 
dysfunction is not only a predictor of hypertension, but also for atherosclerosis [55].  EC 
dysfunction is not the only pathophysiological event that occurs in patients with essential 
hypertension.  The blood vessels of these patients also undergo uncharacteristic vascular 
remodeling. 
1.6.4 Vascular Remodeling in Hypertension 
As mentioned in the anatomy and physiology section, blood vessels are comprised 
of ECs, SMCs, and fibroblasts interacting via autocrine and paracrine signaling.  These 
intercellular interactions are responsible for maintaining normal vascular flow and 
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pressure.  Characteristically, the endothelium interprets environmental signals found in 
blood and transforms them into intracellular signals, which induces a specific cellular 
response from SMCs and/or fibroblasts.  A normal cellular response that stems from 
these environmental cues is vascular remodeling.  However, adverse vascular remodeling 
can occur in response to inimical conditions like high blood pressure; vascular 
adaptability allows cardiovascular diseases to persist at the expense of normal vessel 
structure and function. [56,57,58]. 
Vascular remodeling is represented by changes in vessel structure that could alter 
four important cellular activities: cell growth, cell death, cell migration, and the 
production and/or degradation of ECM components.  Growth factors, vasoactive 
substances, and physical stimuli (i.e. pressure or flow) govern the onset of vascular 
remodeling.  Changes in the structure and function of blood vessels can be indicative of 
different vascular diseases playing a part in its pathophysiology.  For example, Figure 9 
below shows three different scenarios where blood vessels undergo remodeling under 
different disease conditions. 
 
Figure 9. Vascular Remodeling in response to uncharacteristic pressure, flow, and injury9 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
9 Renna, N. F., Heras, N. D., & Miatello, R. M. (2013). Pathophysiology of Vascular Remodeling in Hypertension. 
International Journal of Hypertension, 2013, 1-7. doi:10.1155/2013/808353 
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Vessel A and B features an artery that has a reduced luminal diameter and increased 
vessel wall thickness attributed to high blood pressure.  The increase in wall thickness 
stems from an increase in SMCs in the media and an increase in ECM proteins.  As a 
result, peripheral resistance increases and denotes the presence of hypertension.  In 
Figure 9, vessels C and D provides the opposite scenario where an artery’s luminal 
diameter increases because of high blood flow or to increase blood flow.  This scenario 
could occur if patient with high blood pressure is treated with anti-hypertensive 
medication to counteract the vasoconstriction that is accompanies hypertension.  The 
luminal diameter is what is predominantly changing in this case, not so much the cellular 
and ECM components of the vessel wall.  Lastly, vessels C and D show an 
atherosclerotic vessel that impedes normal blood flow and increasing blood pressure 
through plaque formation leading to a smaller lumen diameter [58].  As briefly mentioned 
in the last section, hypertension is a major risk factor for atherosclerosis.  All of these 
scenarios can stem from hypertension. 
Scientists have noted from seminal studies that growth in the vessel wall, 
hypertrophy, stemmed from elevated blood pressure levels.  Since then, Mulvany claimed 
that vascular remodeling should encapsulate any change in vessel diameter in its relaxed 
state.  This ensured that only structural factors contributed to the change in diameter.  
However, this classification of vascular remodeling would be hard to maintain because 
arteries vary in size and other factors like vascular tone, transmural pressure, and vessel 
compliance would have to remain constant.  As a result, Feihl et al formed a more 
pragmatic classification process based on the increase of the media to lumen ratio of 
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blood vessels as blood pressure increases [57].  Referring back to Figure 9, it is 
important to reiterate that both cellular and non-cellular components contribute to the 
remodeling of the vessel’s lumen diameter.   
The definition of remodeling has been refined to include the changes vessels 
experience under hypertension over the years.  A remodeling index for vascular 
remodeling due to several pathologies including hypertension and atherosclerosis can be 
seen in Figure 10 below. 
 
Figure 10. Remodeling index for several pathologies10 
This thesis will be primarily concerned with the hypertrophic growth of conductance 
arteries (i.e. large arteries) characterized by the increase of vessel wall material, which 
ultimately leads to increased arterial stiffness. 
1.6.5 Essential Hypertension Effects on Arterial Structure 
 Large arterial stiffness can be measured using pulse wave velocity, which 
correlates to an increase in blood pressure [1,58].  Unlike small diameter arteries, SMC 
contractility plays a minimal role in the mechanical functionality and arterial stiffness of 
large arteries.  Instead, arterial stiffness is determined principally by ECM proteins elastin 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
10 Renna, N. F., Heras, N. D., & Miatello, R. M. (2013). Pathophysiology of Vascular Remodeling in Hypertension. 
International Journal of Hypertension, 2013, 1-7. doi:10.1155/2013/808353 
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and collagen found in the arterial walls of large arteries [14].  As stated in the physiology 
section, elastin provides adequate stretching of large arteries during systole and collagen 
provides the fortitude necessary to withstand physiological and elevated blood pressures.  
However, persistent disease and aging causes elastin degradation and consequently 
arterial stiffness.  Increased arterial stiffness can foreshadow cardiovascular mortality in 
patients with high blood pressure, end-stage renal failure, and diabetes [1].  Furthermore, 
increased arterial stiffness causes the heart to pump harder to overcome the peripheral 
resistance of the arteries, which hastens its eventual failure. 
 As described in the anatomy and physiology section, elastin is found in the tunica 
media of large arteries and creates a tight network of fibers that encapsulate 
circumferentially oriented SMCs and collagen fibers.  Recall that the complete structural 
unit comprised of elastin, SMCs, and collagen is referred to as lamellae.  The number of 
lamellae found in the tunica media is predetermined during development and depends on 
the amount of loading an artery will experience.  In a relaxed artery, the elastic fibers 
appear rippled.  Under physiological pressure, the elastic fibers stretch out almost 
completely due to the increased mechanical load.  Similarly, collagen fibers appear 
rippled in a relaxed artery, but under physiological pressure, less than 10% of the 
collagen fibers stretch out due to the increased mechanical loading.  When subjected to 
higher blood pressures, more and more collagen fibers stretch out, which increases the 
stiffness and decreases the elasticity of the artery.  This causes arteries to exhibit a 
nonlinear behavior [1]. 
 The composition of the arterial elastin is wholly dependent on the secretion of 
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components by elastogenic cells during late embryonic and neonatal periods of 
development where elastin and supplementary proteins are expressed at elevated levels.  
Elastogenic cells (i.e. SMCs, ECs, and fibroblasts) secrete tropoelastin, the soluble 
monomer of elastin [59].  Elastin aggregates then form on the elastogenic cell surface 
with assistance from lysyl oxidase, a crosslinking enzyme, and fibulin-4/fibulin-5 helper 
proteins.  After initial crosslinking, the aggregates are transported from the cell surface to 
microfibrils comprised of fibrillins, MAGPs, and fibulins.  Further assemblage and 
crosslinking is achieved on the microfibrils producing mature, developed elastin.  Since 
elastin is formed during early development, emulating elastin formation in adults proves 
to be an ongoing challenge [1]. 
 Premature stop mutations, large intragenic deletions, and complete gene deletions 
are all classified as loss of function mutations cause suprvalvular aortic stenosis (SVAS).  
This autosomal dominant disease typically affects the elastin content of large arteries, 
which in turn, causes hypertension and increased arterial stiffness leading to cardiac 
failure or death.  Additionally, SMCs are hyperplastic and hypertrophic and the lamellae 
structure and ECM composition is abnormal under this pathological condition.  This 
mutation occurs because of an unstable mRNA transcript that is subsequently destroyed 
via nonsense-mediated decay or by the production of a non-functional protein that does 
not contain the exons required for reacting with microfibrils [1]. 
 Developmental mice models that remove the elastin gene, ELN, have shown that 
mice without the elastin gene experienced increased arterial stiffness before elevated 
blood flow and blood pressure levels were seen.  Eventually, the mice without elastin die 
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because the arteries are unable to withstand the increasing arterial pressure in developing 
mice.  The soluble form of elastin, tropoelastin, also serves as a signaling molecule that 
inhibits SMC proliferation, influences the organization of actin fibers, and promotes 
chemotaxis of cells.  Another study predisposed mice to SVAS and as expected, these 
mice experienced elevated blood pressure levels and increased arterial stiffness.  In vitro 
mechanical analysis of vasculature at different stages of development reinforced the 
claim that arterial stiffness increases before blood pressure.  During development, mice 
with SVAS formed more lamellar units in their arteries due to the increase in blood 
pressure, which is similar to what is found in adult humans with the same disease.  The 
increase in lamellar units coupled with the inability to remodel the arterial ECM in 
adulthood when exposed to high blood pressure insinuates that the bulk of remodeling 
arterial structure occurs during development.  This phenomenon can be attributed to SMC 
progenitor cells located in the adventitia that has the ability to create more lamellar units. 
 Large elastic arteries serve to expand during systole and recoil during diastole, 
which helps push the blood through the systemic circuit.  As the stiffness of these large 
arteries increases, more pressure is required to distend the vessel wall.  When the heart 
pumps blood into the systemic circuit, a pressure wave travels at a specific pulse wave 
velocity (PWV) depending on arterial thickness, the timing and magnitude of wave 
reflections, and by viscosity and inertia losses.  Pressure wave reflections occur at arterial 
branches and at the regions of increased stiffness.  These reflected waves makes their 
way back to the aorta subsequently increasing blood pressure levels throughout the 
systemic circuit.  PWV is lower in younger individuals and wave reflections arrive at the 
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aorta later increasing diastolic pressure compared to older adults where PWV is increased 
and wave reflections arrive earlier increasing systolic pressure.  Increased arterial wall 
stiffness results in increased pressure wave reflections, which induces high blood 
pressure.  PWV can be a clinical indicator because it increases before increased blood 
pressure could be seen [1,61]. 
1.6.6 Limitations in Lame’s Equation and Pulse Wave Velocity 
Under essential hypertension, large arteries undergo vascular remodeling where 
the intima and media increase in thickness by about 15-40% and the lumen enlarges, 
especially in proximal elastic arteries such as the human common carotid artery.  The 
thickening of the vascular wall attempts to accommodate the increase in blood pressure 
and tries to maintain normal circumferential wall stress as described by Lamé’s equation, 𝜎! = !∗!!  where stress increases as blood pressure (P) and lumen radius (R) increases and 
decreases as arterial thickness (h) increases.  Note that Lame’s equation was mentioned in 
Section 1.4 and in Figure 4.  However, circumferential wall stress remains elevated 
because of the larger lumen seen in arteries subjected to high blood pressure, which 
counteracts the increase in intima-media thickness caused by SMC proliferation. 
Referring back to Lamé’s equation, the increase in intima-media thickness cannot 
compensate for both high blood pressure and the larger lumen size.  A stark limitation of 
Lamé’s equation is that it does not describe arterial stiffness, which as indicated above 
can be an indicator of high blood pressure before elevated blood pressure levels can be 
directly measured in the human body.  When the ventricle pumps the blood into the 
systemic circuit, part of the stroke volume is pumped through the systemic arteries, 
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directly into the surrounding tissue and the other part of the stroke volume is stored in the 
walls of distending large elastic arteries.  During diastole, the distended walls of the large 
elastic arteries recoil back to its normal position pushing more blood through to the rest 
of the peripheral arteries and tissues.  This process ensures that blood is pumped 
continuously throughout the systemic circuit, but is negatively impacted due to increased 
arterial stiffness.  In conclusion, Lame’s equation is an oversimplification of the complex 
vascular mechanics experienced in hypertension.  Future mathematical models 
compensating for arterial mechanics need to be developed using data from experimental 
models.  Pulse wave velocity (PWV) tries to account for arterial stiffness. 
PWV, measured using ultrasound, is the easiest way to measure arterial stiffness 
because the procedure is non-invasive and repeatable.  The time delay of the waveform is 
measured between two points along the aortoiliac conduit.  The time delay (Δt) and the 
distance (D) between the two points can be used to calculate the carotid-femoral pulse 
wave velocity (cfPWV) using the equation 𝑐𝑓𝑃𝑊𝑉 = !  (!)!!  (!), which serves as an accurate 
predictor of arterial stiffness.  Typically, people with high blood pressure have 
concomitant high cfPWV values.  Furthermore, improved technological echo-tracking 
devices have made it easier to accurately measure an artery’s internal diameter, stroke 
volume, and wall thickness under the assumptions that the artery’s diameter is completely 
circular and the arterial wall distributes he load evenly.  Only with these assumptions can 
Young’s modulus be used to calculate the elasticity of an artery [60,61].  Despite 
mathematical limitations, PWV can be useful for determining the onset of hypertension. 
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1.6.7 Summary: Short-term effects of elevated blood pressure 
 As blood pressure increases, more collagen fibers are deposited in the arterial 
ECM and become stretched increasing arterial stiffness.  Typically, mean arterial 
stiffness increases when the cardiac cycle transitions from diastole to systole as the blood 
pressure increases and the arterial walls distend.  Thus, the pressure-distensibility curve 
generated for each cardiac cycle has a negative slope, which indicates that arteries are 
stiffer and jumps in stiffness are larger at higher blood pressure levels.  Patients who have 
high blood pressure have pressure-distensibility curves that are shifted towards the right, 
which shows the increase in arterial stiffness [62].  Depictions of these distensibility 
curves are featured in Figure 11 below. 
 
Figure 11. A) Distensibility curve of carotid artery for normotensive and hypertensive patients B) 
Distensibility curve of radial artery for normotensive and hypertensive patients11 
1.6.8 Summary: Long-term effects of elevated blood pressure 
 In the long run, patients with hypertension will experience higher levels of cyclic 
loading that will lead to the mechanical fatigue of the arterial walls.  The elastic fibers 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
11 Laurent, S., & Boutouyrie, P. (2015). The Structural Factor of Hypertension: Large and Small Artery Alterations. 
Circulation Research, 116(6), 1007-1021. doi:10.1161/circresaha.116.303596  	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become degraded and are replaced by stiffer collagen fibers and calcium deposition 
decreasing arterial elasticity.  The normal turnover of the ECM is disrupted and higher 
blood pressure promotes higher degradation rates of elastin and collagen via elastases and 
collagenases secreted by the inflammatory cells, macrophages and neutrophils, leading to 
the alteration of mechanical properties.  Macrophages and neutrophils can also release 
metalloproteinases (MMPs) and cytokines, which expedite the ECM degradation process.  
Additionally, the renin-angiotensin system is activated causing SMCs to proliferate and 
increase arterial stiffness [62].   
1.7 Treatment and Therapeutic Options for Essential Hypertension  
1.7.1 Dietary Changes 
 The cheapest therapy, albeit the least effective, used to combat hypertension and 
EC dysfunction is dietary changes, especially by restricting sodium intake.  A reduced 
sodium intake produces meager results, about a 5 mmHg decrease in systolic pressure 
and approximately a 2.7 mmHg drop in diastolic blood pressure.  Despite these 
discouraging statistics, a large population that reduces their sodium consumption can 
qualify the onset of EC dysfunction and hypertension exacerbated by a high sodium 
intake, which produces increased levels of oxidative stress and decreased availability of 
NO.  The overall outcome would be reduced cardiovascular risk, morbidity, and mortality 
associated with cardiovascular disease that stemmed from EC dysfunction and 
hypertension.  A clinical study took patients with prehypertension and stage-1 
hypertension and monitored their sodium intake.  The group of patients who consumed 
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less than 100 mmol sodium/day showed greater brachial FDA than the group who 
consumed between 100 and 200 mmol sodium/day.  A more recent clinical study 
provided similar results.  147 hypertensive patients were randomized into 1, 3, or 6 
servings of fresh fruits and vegetables per day for 12 weeks after a 4-week diet consisting 
of <1 serving of fruits and vegetables.  The patients that received 3 or 6 servings of fruits 
and vegetables exhibited a 4-5 mmHg reduction in their systolic blood pressure.  
Additionally, endothelium-induced forearm blood flow increased significantly by 6.2% 
for every 1-serving increase in fruits and vegetables.  Although the study did not measure 
sodium intake, an increased consumption of fruits and vegetables should replace foods 
with higher sodium content.  Fruits and vegetables also have a high polyphenol content, 
which increases the production of NO [54].  Unfortunately, dietary changes alone cannot 
completely ameliorate EC dysfunction and hypertension, so the consumption of 
antihypertensive drugs becomes justified. 
1.7.2 Antihypertensive Drugs 
   There are several antihypertensive drugs to choose from and each reverse EC 
dysfunction and hypertension through different mechanisms.  For example, angiotensin-
converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, aldosterone 
antagonists, and nebivolol (a beta-blocker) can decrease blood pressure and normalize EC 
functionality.  Newer medications such as calcium channel blockers and thiazide diuretics 
claim to reduce blood pressure and repair EC function, but studies have produced 
inconsistent results [54,55].  These drugs holistically operate through different 
mechanisms not fully understood and though they may reduce blood pressure, these 
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drugs may not have an effect on EC functionality. 
 Since essential hypertension and compromised endothelial vasodilation could lead 
to the development of atherosclerotic lesions as mentioned in the previous section, 
reversing endothelial dysfunction and correcting endothelial-mediated vasodilation is an 
important aspect to consider when undergoing antihypertensive therapy.  Returning blood 
pressure to normal is not enough to resolve the attenuated endothelial vasodilatory 
response to acetylcholine or methacholine seen in hypertensive patients.  This 
corroborates the proposition that antihypertensive drug should not only reduce blood 
pressure, but also return endothelial functionality to normal.  Thus, antihypertensive 
drugs need screening in relation to their effects on endothelial functionality.  Laboratory 
studies have established the fact that a majority of the antihypertensive drugs enhance 
endothelium-induced vasodilation.  These drugs operate through different mechanisms 
like upregulating NO synthase activity, increasing free-radical scavenger activity, or by 
reducing the production of reactive oxygen species.  Despite promising experimental 
studies, subsequent animal and clinical trials failed to replicate the same positive effects 
[55].  Before reviewing the different types of antihypertensive drugs and the results from 
their corresponding clinical trials, it is important to highlight four discernible issues with 
the pharmacological approach to ameliorating the effects of hypertension.   
Firstly, different drugs may be more suitable for certain patients wholly dependent 
upon the patient-specific pathology.  For example, some drugs have a significant effect 
on patients with atherosclerosis and have no effect on patients with essential 
hypertension.  The next issue to consider is that the short-term and long-term effect of a 
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drug can differ considerably.  Results from a short-term drug study do not immediately 
certify that a drug is effective against essential hypertension because essential 
hypertension is a persistent and chronic disease.  Another issue lies in the fact that 
endothelial functionality relies on autocrine-paracrine signaling, which varies from artery 
to artery.  Results from studies that target a specific region of arteries cannot apply to 
other arterial regions.  The last consideration takes into account that endothelium-induced 
vasodilation depends on NO availability, so drugs that cause vasodilation through other 
cellular mechanisms may or may not correspond to an increase in NO production [55]. 
1.7.3 β-Blockers 
 No studies have previously investigated the relationship between classical β-
adrenoceptor antagonists (β-blockers) and endothelial-induced vasodilation.  In spite of 
this, the β-blocker, atenolol, served as a control drug paradigm in several studies testing 
the efficacy of antihypertensive drugs including calcium channel antagonists and 
angiotensin converting enzymes (ACE) inhibitors.  Numerous studies conducted by 
Schiffrin and his lab group concluded that patients who used atenolol for 1-year did not 
normalize their reaction to acetylcholine.  An extended study verified Schiffrin’s 
conclusions by producing similar results.  Patients who took atenolol for 3 years did not 
ameliorate endothelium-dependent vasodilation in response to both acetylcholine and 
bradykinin when injected into the patients’ forearm.  Despite the initial negative 
discoveries, newer β-blockers have shown to induce vasodilation.  Nebivolol, a selective 
β-blocker, induced vascular relaxation.  Dawes et al conducted a study where healthy 
	  	   44	  
participants received nebivolol infusions at therapeutic levels in their brachial artery 
reported a moderate increase in forearm blood flow (FBF).  Infusion with L-NMMA 
diminished the effects nebivolol, but nebivolol continued to work in the presence of L-
arginine and NO synthase inhibitors.  These two characteristics support the idea that 
nebivolol produces NO-dependent vasodilation.  However, the opposite held true in 
patients with essential hypertension.  Preliminary results from Taddei et al revealed that 
nebivolol did not have a vasodilatory effect unless it was in the presence of ascorbic acid, 
an antioxidant.  The combination of nebivolol and ascorbic acid promoted vasodilation 
and responded to L-NMMA administration.  Additionally, nebivolol has no effect when 
ingested orally, so intravenous administration of the drug is not sufficient in determining 
its cellular mechanism.  Future studies will elucidate the underlying mechanisms 
governing nebivolol-induced vasodilation for both oral and intravenous administration.  
Finally, the discovery of a novel β-blocker called carvedilol could repair endothelial 
functionality because of its bonus α1-adrenoceptor antagonist characteristics and 
heightened antioxidant effects.  Initial studies displayed carvedilol’s ability to cause 
vasodilation and increase flow in the brachial artery of patients with essential 
hypertension [55]. 
1.7.4 Calcium Channel Antagonists 
  Data from several animal studies confirm that calcium channel antagonists 
induce endothelium-dependent vessel relaxation.  Furthermore, the dihydropyridine class 
of drugs has a positive reparatory effect on endothelial functionality across a diverse 
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range of vascular beds in patients with essential hypertension.  The valuable qualities of 
calcium channel antagonists were first apparent in the coronary vascular bed.  A clinical 
study compared the effects of two calcium channel antagonists, dihydropyridine 
nicardipine and benzothiazepine-like diltiazem, on vasoregulation in normal and stenotic 
epicardial coronary arteries of both normotensive and hypertensive patients during 
exercise.  Normotensive patients with healthy coronary arteries exhibited coronary 
vasodilation during exercise.  Patients with essential hypertension and healthy arteries did 
not demonstrate vasodilation during exercise indicating the onset of EC dysfunction.  
Vasoconstriction occurred in normotensive patients with stenotic coronary arteries during 
exercise.  Patients with both essential hypertension and stenotic coronary arteries 
displayed a heightened vasoconstrictive response during exercise.  Abnormal 
vasoconstriction to exercise correlates to severe EC dysfunction.  However, the two 
calcium channel antagonists did restored normal EC functionality in normotensive 
patients with stenotic arteries, hypertensive patients with non-stenotic arteries, and 
hypertensive patients with stenotic arteries.  Whether the drugs reversed EC dysfunction 
by increasing NO production or through a different cellular interaction remains uncertain.  
Another clinical trial called the Evaluation of Nifedipine and Cerivastatin sodium on 
Recovery of Endothelial Function (ENCORE) tested the efficacy of nifedipine GITS 
(gastroeintestinal therapeutic system), the HMG-CoA reductase inhibitor cerivastatin, and 
a combination of nifedipine and cerivastatin in patients who have atherosclerotic 
coronary artery disease.  Each calcium-channel antagonist therapy had enhanced 
responsiveness to acetylcholine when compared to the placebo group.  Another study 
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infused amlodipine into the brachial artery of hypertensive patients.  After two months of 
infusions, each patient’s brachial artery underwent vasoconstriction when injected with 
L-NMMA supporting the idea that amlodipine could return NO availability to normal 
levels.  However, since reduced NO availability stems from high blood pressure levels, 
the normalization of NO levels could just be in response to lowered blood pressure levels 
and not amlodipine itself.  Furthermore, hypertensive patients treated with lacidpine 6 
mg/day for 2 and 8 months considerably enhanced the vasodilatory response to 
acetylcholine.  Lastly, a study that treated patients with nifedipine GITS 60 mg/day for 6 
months also increased vasodilation in the presence of acetylcholine and attenuated 
vasoconstriction caused by phenylephrine and endothelin-1.  These two studies 
confirmed the vasodilatory effect of calcium channel antagonists [55]. 
 The mechanism in which calcium channel antagonists reverse endothelial 
dysfunction and restore NO levels is not calcium dependent, but depends on the 
antioxidant property of calcium channel antagonists.  Being antioxidants, these drugs 
shield ECs from reactive oxygen species and prevent damage to the NO pathway.  
Nifedipine GITS 30-60 mg/day administered to hypertensive patients over the course of 3 
months still rendered a moderate vasodilatory response to acetylcholine, but combatted 
L-NMMA inhibition indicative of increased NO production.  These findings confirm the 
theory that nifedipine reverses EC dysfunction and fixes the NO pathway through its 
antioxidant capabilities.  Taddei et al produced similar results in a double blind, 
randomized study in which patients took either lacidipine (calcium channel antagonist) or 
atenolol (β-blocker).  After 3-months, only patients who took lacidipine displayed 
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vasodilation in response to acetylcholine and bradykinin and resisted L-NMMA 
inhibition.  Additionally, only lacidipine decreased plasma lipoperoxide, LDLs, and ROS 
highlighting the antioxidant ability of calcium channel antagonists.  Despite the positive 
results in small arteries, ambiguity surrounds the effects of dihydropyridine calcium 
channel antagonists on large peripheral arteries.  In conclusion, calcium channel 
antagonists serve to reverse endothelial dysfunction and repair the NO pathway in 
different areas of vasculature ranging from the coronary arteries to small peripheral 
arteries due to its antioxidant property [55]. 
1.7.5 Angiotensin Converting Enzyme (ACE) Inhibitors 
 ACE inhibitors preserve and increase bradykinin, a protein vasodilator, in 
circulation by preventing its degradation.  Additionally, angiotensin II contributes to EC 
dysfunction by down-regulating NO synthase activity or by activating NADH-oxidase 
leading to elevated levels of oxidative stress, so ACE inhibitors can suppress angiotensin 
II levels.  ACE inhibitors bolstered positive results in the spontaneously hypertensive rat 
(SHR) and L-NAME-induced hypertension animal models, but definitive results were not 
replicated in human trials.  Cilazapril treatment heightened the vasodilatory response to 
acetylcholine in the subcutaneous microcirculation of hypertensive patients when treated 
with the ACE inhibitor for 2 years.  The same outcome was reported for lisinoprol 
administered to patients over the course of 3 years.  Perindoprilat corrected endothelial-
dependent vasodilation in the epicardial coronary arteries of hypertensive patients who 
were subjected to cold-pressure tests and induced flow-mediated dilation.  Taddei and his 
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lab group produced the same positive effects in peripheral large arteries.  Perindopril, 
administered at 4 mg/day for 6 months to patients with essential hypertension, amplified 
flow-mediated vasodilation.  Similarly, administering ramipril to hypertensive patients at 
10 mg/day for 4 weeks caused vasodilation of the brachial artery.  The effects of ramipril 
engendered L-NMMA activity indicating that the ACE inhibitor has antioxidant 
properties capable of elevating NO levels.  Higashi et al showed that ACE inhibitors not 
only improved NO availability, but could also reverse aberrant vascular remodeling as 
seen in ischemic, hypertensive patients [54,55]. 
1.7.6 Angiotensin-II Receptor Antagonists 
  Several studies portray the adverse effects angiotensin II has on endothelial 
function.  Angiotensin II promotes the production of vasoconstrictors like ET-1 and 
prostanoid PG H2 by ECs and prevents NO synthase activity by enabling protein kinase 
C.  Additionally, angiotensin II causes SMCs to release more oxygen free radicals using 
their NADPH oxidases, which hinders vasodilation in response to acetylcholine.  
Losartan, an angiotensin type-1 receptor antagonist, fosters physiological vasodilation 
and lowered oxygen free radical levels in the presence of angiotensin II molecules.  Since 
these antagonists bind to AT1 receptors, angiotensin II can only bind to AT2 receptors 
increasing NO production from ECs.  Vasodilation in response to acetylcholine increased 
in the subcutaneous microcirculation when hypertensive patients received 50-100 mg/day 
of lorsatan for a year.  However, vasodilation in response to acetylcholine and normal L-
NMMA inhibition was not achieved in the forearm microcirculation when patients 
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received between 8 and 16 mg/day of candesartan for a year.  Despite preliminary 
negative results, candesartan prevented vasodilation caused by TAK-044, a nonspecific 
antagonist of endothelin-1.  TAK-044 is raised in hypertensive individuals, which in turn 
stimulates ET-1 vasoconstriction.  Candesartan disrupts the positive feedback loop, which 
could normalize vascular function and reverse unwanted vascular remodeling linked to 
ET-1.  Furthermore, AT1-receptor antagonists do not work on large arteries.  Taddei et al 
administered telmisartan at a dose of 40 to 80 mg/day for 6 months to patients with 
essential hypertension, which did not restore flow-mediated vasodilation of large arteries.  
Overall, conflicting results fail to comfortably discern the ability of AT1-receptor 
antagonist in restoring endothelial functionality for patients with essential hypertension.  
Since antihypertensive effects vary across artery groups and the reversal of EC 
dysfunction is not guaranteed, a resolute pharmacologic paradigm remains to be 
developed [54,55]. 
1.7.7 Contention Regarding an Ideal Antihypertensive Treatment Paradigm 
With a plethora of antihypertensive drugs to choose from, the debate as to which 
antihypertensive drugs to use first continues.  A large clinical study, The 
Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 
that concluded in 2002 provided the basis for antihypertension therapeutic guidelines 
released a year later in 2003.  The guidelines supported the use of diuretics as the initial 
treatment for hypertension because of its low cost and the pleiotropic effect other drugs 
demonstrated similar antihypertensive effects.  ALLHAT assembled a group of 
individuals at least 55 years of age that displayed hypertension and qualified for 
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antihypertensive drug therapy.  Randomization into three test groups according to 
antihypertensive drugs ensued where subjects in group 1 took chlorthalidone (a diuretic), 
subjects in group 2 took amlodipine (a calcium channel blocker), and subjects in group 3 
took lisinopril (an ACE inhibitor).  At a mean follow-up of 4.9 years, there was no 
significant difference in each of the three groups measured by the incidence of fatal heart 
disease and nonfatal myocardial infarctions.  In the end, chlorthalidone proved better than 
amlodipine in relation to heart failure and lisinopril in relation to antagonistic 
cardiovascular events.  However, this clinical study had its limitations and shortcomings.  
ALLHAT’s findings do not substantiate an accepted pharmacologic strategy to reduce 
hypertension.  The patients who participated in the study were on average around 67 
years old.  They had a history of hypertension and were already taking antihypertensive 
drugs before the beginning of the study.  Additionally, these individuals demonstrated 
atherosclerosis.  Finally, the reduction in blood pressure was actually greater for the test 
group who took chlorthalidone despite the claim contrived by ALLHAT stating that there 
was no significant difference in the antihypertensive effects of diuretics compared to 
other drugs.  These results would not apply to younger patients and for patients who have 
shorter disease durations and less vascular damage when initially diagnosed with 
hypertension.  ALLHAT overlooked the ancillary beneficial effects of other 
antihypertensive drugs if high blood pressure was constant.  Other clinical studies have 
displayed the combinatorial effects of antihypertensive drugs that refute the preliminary 
data released by ALLHAT.  For example, the Losartan Intervention for Endpoint 
Reduction in Hypertension (LIFE) clinical trial proved that angiotensin II receptor 
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blockers (commonly known as losartan) were all around better for hypertensive 
individuals between ages 55 and 80 when compared to atenolol-based drug therapies 
despite producing similar reductions in blood pressure levels.  The patients in this study 
took these drugs in combination with a diuretic therapy to achieve optimal results.  
Another randomized clinical trial compared the effects of enalapril (an ACE inhibitor) 
and hydrochlorothiazide (a diuretic) in hypertensive patients between ages 65 and 84.  
Results maintained that enalapril was actually better for the patients, especially men.  The 
latest clinical study called Avoiding Cardiovascular Events through Combination 
Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) showed that 
ACE inhibitors combined with amlodipine was better than the combinatorial efficacy of 
ACE inhibition-diuretic therapies.  This study highlights the antioxidant capabilities of 
thiazide therapy and its pronounced effect on vascular homeostasis.  These three studies 
have proven that diuretics may not be suitable for all hypertensive patients.  Since 
reversing endothelial dysfunction is an added benefit for reducing blood pressure, 
investigations are ongoing in order to find the optimal antihypertensive therapy that 
reduces hypertension as well as correcting endothelial dysfunction.  Despite the strides 
made in drug development, antihypertensive drugs fail to remedy the adverse vascular 
remodeling experienced within patients with hypertension [54]. 
1.7.8 Vascular Grafts and their Limitations 
 As previously discussed, hypertension causes adverse vascular remodeling.  
Additionally, elevated blood pressure levels can be the leading cause of other vascular 
disease states (i.e. aneurysms and atherosclerosis) that impede normal blood flow.  Thus, 
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revascularization techniques are necessary to return blood flow to normal and the most 
common method is the implantation of autologous or synthetic bypass grafts.  Bypass 
grafts are surgically anastamosed to diseased blood vessels in a fashion that navigates 
blood flow around the diseased site.  Large diameter bypass grafts boast high patency 
rates, but are also associated with other severe complications; these grafts may not be 
suitable for high-risk patients.  Although autologous grafts are preferred, a patient may 
not have viable veins and arteries required for the surgical procedure.  The other 
alternative would be to use  natural or synthetic materials such as collagen, polyester, 
Dacron®, polytetrafluoroethylene (PTFE), or expanded PTFE like Gortex®.  Despite 
their ubiquity in treating patients with diseased blood vessels, these synthetic vessels 
possess several complications and limitations. 
 One uncommon complication is graft infection with reported incidences as low as 
1-3% to as high as 6%.  Even though the occurrence is low,  between 25% and 88% of 
patients who contract graft infections die and 5-25% of patients with graft infections 
require limb amputations.  The second complication is related to intimal hyperplasia at 
the anastomosis sites.  Increased cell proliferation and ECM deposition at these sites lead 
to stenosis and ultimately, graft failure.  This complication can be attributed to abnormal 
flow dynamics and lack of endothelialization.  Additionally, the lack of endothelialization 
of synthetic small diameter grafts (4-5 mm) causes thrombosis.  Lastly, other 
complications include abnormal graft dilation due to compliance mismatch and 
pseudoaneurysms [63].  All of these complications potentiate the need for a tissue-
engineered alternative. 
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1.8 Tissue-Engineered Blood Vessels and Current Challenges 
 Despite available antihypertensive medications and vascular grafts, these options 
fail to simultaneously fix both EC dysfunction and adverse vascular remodeling that 
accompany essential hypertension while upholding a vessel’s physiological structure and 
functionality.  These limitations potentiate the need for tissue engineered blood vessels 
(TEBVs) as a therapeutic option for treating essential hypertension. 
Since the advent of tissue engineering, TEBVs have been synthesized and studied 
as a potential treatment option for a lot of cardiovascular diseases.  Significant progress 
has been made with regards to TEBVs, but glaring hurdles still need to be overcome.  In 
order to create functional blood vessels: (1) a nonthrombogenic and nonimmunogenic 
surface that interacts with blood needs to be further developed; (2) the synthetic vessel 
should have the same material and mechanical properties as native vessels; and (3) 
functional vasoregulation needs to be achieved.  Once a functional blood vessel can be 
generated in lab, the process should be scaled up efficiently and economically to reduce 
the time and cost to produce these constructs; this ensures that TEBVs would be a 
competitive alternative to current treatment methods.  Furthermore, FDA regulations 
should be considered when making TEBVs.  These requirements are stringent, but are 
required and drive TEBV innovation and development.  There are three accepted and 
proven methods for creating TEBVs for clinical therapies [64].   
The first method involves the in vitro seeding of cells onto a biodegradable 
synthetic or biological scaffold; these constructs will undergo further conditioning in a 
bioreactor.  The cells in the scaffold will react to the physiological stimuli generated by 
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the bioreactor, which essentially functionalizes the TEBV.  For example, fluid shear 
stress will induce ECs to produce NO and prostacyclin.  These vasodilatory agents 
mentioned previously will cause SMCs to relax and the blood vessel as a whole to dilate.  
The SMCs also respond to the in vitro shear stress by synthesizing more ECM proteins 
and enable vascular remodeling of the TEBV.  The scaffold alone does not respond to 
physiological stimuli, but is important in mimicking the structural and mechanical 
properties of a native blood vessel as well as providing attachment sites for cells.  
Although there are positive aspects associated with this method, there are also some 
drawbacks.  A patient’s immune system will reject these TEBVs if the attached cells are 
not autologous, so cells would have to be isolated from patients and meticulously grown 
in vitro before seeding.  Patient specific cell isolation would prove to be costly and would 
have to pass the strict regulations set by the FDA.  Patient-specific cell isolation and 
expansion would also extend the time it takes to manufacture these vessels and eliminate 
the off-the-shelf availability delaying its implantation into patients.  The current method 
seems impractical for clinical use, but future studies are focusing more on isolating 
readily available cells at or around the implantation site, which would completely 
eliminate the ex vivo culture period [64]. 
The second method exploits a cell’s ability to self-assemble.  Cells will interact 
and form cell sheets, so a scaffold is not required in this tissue engineering method.  
Stacking and subsequent rolling of these cells sheets can produce functional TEBVs.  
Ideally, a cell sheet of SMCs will form the functional media of a blood vessel that is 
capable of responding to physiological stimuli.  A cell sheet of ECs laid on top of the 
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SMC layer would form the intima and provide a non-thrombogenic surface that stays in 
contact with blood.  As with the first method, autologous cells would still have to be 
isolated and cultured prolonging TEBV preparation time for implantation.  Allogeneic 
mesenchymal stem cells have been utilized in clinical trials and proved to be 
immunosuppressive.  However, these cells are not antithrombotic, so ECs are still needed 
to make the intima layer [64]. 
The last method focuses entirely on the in vitro decellularization of allogeneic and 
xenogeneic vascular grafts.  These decellularized grafts are non-immunogenic and can be 
seeded with autologous cells or allogeneic stem cells before implantation.  The 
decellularized grafts can be stored for prolonged periods making them readily available 
off the shelves.  However, current acellular grafts are lacking in several mechanical 
properties and need to be reinforced using synthetic polymer materials.  The polymer 
material has to be resorbed at the same rate as natural vascular remodeling in order to 
create an ideal vessel that has the correct burst strength and compliance.  Like their 
synthetic counterparts, thrombosis remains a problem for TEBVs that are <6 mm in 
diameter, so endothelialization is still necessary after implantation.  Furthermore, in vivo 
conditioning of decellularized grafts may not be achievable due to limited vascular 
remodeling, vasoactivity, and endothelialization found in patients with cardiovascular 
diseases.  Current research projects investigate quick EC isolation or recruitment at the 
implantation site and also at rapid graft endothelialization techniques.  A few clinical 
trials have tested TEBVs created using these methodologies [64]. 
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1.8.1 Clinical Trials Regarding TEBVs 
 The first clinical trial concerning TEBVs included 25 patients between 1 and 24 
years old who had single ventricle congenital defects.  Autologous bone marrow 
mononuclear cells were used to repopulate a biodegradable scaffold made up of woven 
polyglycolic acid, poly-L-lactide, and ε-caprolactone in a 50-50 ratio to create the TEBV.  
The TEBVs were then implanted within the pulmonary circuit of each patient in a manner 
that bypassed the defect.  At an average follow-up time of 5.8 years, none of the patients 
died from graft complications and the grafts remained patent.  However, stenosis was 
observed in 24% of the patients, but could be treated via balloon angioplasty if the 
severity of the stenosis increased.  The success of the study validated that TEBVs could 
be a suitable substitute for vascular grafts when bypassing low-pressure blood vessels 
[64]. 
Another clinical study conducted by L’Heureux et al employed the cell sheet 
method for creating small-diameter TEBVs.  Autologous human fibroblasts were 
obtained from skin biopsies and autologous ECs were isolated from a superficial vein.  
Cells of each type formed corresponding cell sheets and were rolled into an autologous 
TEBV.  These TEBVs were implanted in 10 hemodialysis patients; the TEBVs displayed 
the mechanical strength necessary to withstand hemodialysis and remained patent for a 
total of 68 months due to the antithrombotic EC layer.  However, the time to make each 
graft was extensive, so L’Heureux and his lab are looking to cut manufacturing times by 
using only allogeneic human fibroblasts and the assembly of 3D vessels from threads of 
cell-synthesized ECM [64].   
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Lastly, Humacyte et al created their TEBV by initially seeding human SMCs onto 
a tubular polyglycolic acid (PGA) scaffold.  After the SMCs produced enough ECM 
proteins, they used detergents to decellularize the construct leaving behind a non-
immunogenic TEBV with sublime mechanical properties.  The TEBVs were implanted as 
an arteriovenous (AV) fistula connecting the axilliary artery and brachial vein of 
baboons.  The TEBVs demonstrated >80% patency for about 6 months and exhibited 
medial layer remodeling as well as partial endothelialization at the anastomosis sites.  
With positive lab and animal model results, Humacyte recruited patients for a multi-
center European clinical trial in December 2012.  The FDA also allowed Humacyte to 
conduct clinical trials using these TEBVs in patients who are unable to undergo AV 
fistula formation due to severe vessel damage in June 2013.  The data from these clinical 
trials are still pending [64]. 
1.8.2 Cell Sources for TEBVs 
 A viable cell source remains an ongoing problem for tissue engineering vascular 
constructs [65].  Ideally, autologous cell sources that can divide indefinitely and can 
differentiate into mature ECs and SMCs are preferred for TEBV applications.  
Consequently, adult stem cells provide a copious amount of autologous cells that can 
proliferate and differentiate into vessel wall cells.  Additionally, adult mesenchymal stem 
cells obtained from human bone marrow, adipose tissue, or muscle can differentiate into 
contractile cells comparable to SMCs [64]. 
 Rapid endothelialization is critical for the functionality of TEBVs with a diameter 
<6 mm.  The jugular or saphenous vein as well as liposuctioned fat serve as a source for 
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autologous human microvascular ECs.  However, the invasive procedure yields a 
marginal amount of cells with short lifespans.  Furthermore, adipose-derived stem cells 
typically become contaminated with other cell types like macrophages and fibroblasts, 
which exacerbate the onset of intimal hyperplasia as seen in a dog model and decreases 
patency as seen in a rabbit model.  Better methods for acquiring autologous ECs are listed 
below: 
(1) Differentiating MSCs into ECs 
(2) Differentiating endothelial progenitor cells (EPCs) into ECs 
(3) Reverting autologous stromal cells back to induced pluripotent stem (iPS) cells 
and then differentiating the iPS cells into ECs 
(4) Trans-differentiating stromal cells into ECs bypassing the need for pluripotent 
cells 
Alternatively, bone marrow stem cells garnered interest because of the abundance of 
mononuclear cells (MNCs) found in the bone marrow of the iliac crest.  Researchers 
believed that these MNCs could be seeded onto TEBVs and differentiated into ECs in 
vivo.  However, MNCs caused vascular remodeling due to inflammation and the addition 
of EC growth factors like vascular endothelial growth factor (VEGF) and fibroblast 
growth factor (FGF) did not promote MNC differentiation into ECs.  Fluid shear stress 
did foster the expression of EC cell markers such as von Willebrand Factor (vWF), 
platelet-endothelial cell adhesion molecule, and VE-cadherin, which indicates that bone 
marrow MSCs could differentiate into ECs [64]. 
Recently, EPCs has burgeoned attention as a source for autologous ECs, which can be 
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harvested from adult or umbilical cord blood.  Two functionally different populations, 
early-outgrowth and late-outgrowth EPCs, can be harvested depending on the isolation 
method used.  Only the late-outgrowth EPCs also known as endothelial colony forming 
cells have high proliferation rates and express physiological EC surface markers and 
functionality.  Late-outgrowth EPCs harvested from either healthy adults or patients with 
cardiovascular disease are senescent and have a low proliferative potential, whereas EPCs 
from umbilical cord blood can divide between 50-60 times before senescence.  
Regardless of origin, late-outgrowth EPCs do not provoke much of an immune response.  
These EPCs also phenotypically and functionally resemble human aortic endothelial cells 
(hAECs).  For example, EPCs express VE-cadherin, CD31, and vWF, which are all 
surface markers corresponding to ECs.  They also take up acetylated low-density 
lipoproteins, induce vasodilation in response to normal NO levels, align in the direction 
of flow, and up-regulate EC genes like Kruppel-like factor 2, eNOS, cyclo-oxygenase 2, 
and thrombomodulin due to flow.  Jantzen et al demonstrated that porcine EPCs can 
attach and proliferate inside titanium tubes when exposed to physiological flow and shear 
stress in vitro.  After conditioning, they implanted these EPC-coated Ti tubes in the 
inferior vena cava, which is known for its pro-thrombotic environment due to low shear 
stress; after 3 days, the tubes were explanted and analyzed for thrombosis.  Jentzen et al 
discovered that the EPC coated titanium tubes prevented thrombosis even when exposed 
to an environment with low shear stress [65].  A separate study conducted by Stroncek 
and his lab harvest human EPCs from patients with cardiovascular disease and seeded 
them onto poly-tetrafluoroethylene vascular grafts.  These grafts were then anastamosed 
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onto the femoral artery of several rats and they exhibited 75-88% patency over the course 
of 28-days albeit intimal hyperplasia was seen at the anastomosis sites [65]. 
 Vascular SMCs on the other hand exhibit more of a contractile phenotype with 
low proliferative tendencies.  Without the ability to secrete necessary ECM components, 
TEBVs will not have adequate mechanical properties.  Ongoing research has focused on 
transitioning SMCs from an initial synthetic phenotype to a more contractile phenotype; 
both phenotypes play distinct roles in vessel functionality.  Similar to ECs, bone marrow 
MNCs, bone marrow MSCs, adipose stem cells, and skeletal muscle can differentiate into 
cells with vascular SMC traits, but these sources also have the same complications 
highlighted in the previous paragraph.  A better alternative would be to use iPS cells 
obtained from de-differentiating late-outgrowth EPCs.  The reversal process of EPCs is 
easy and produces iPS cells with low variability meaning that these cells could be 
differentiated into SMCs with distinct phenotypes, which can be used in TEBVs. 
 Pinpointing viable cell sources is an important research area that is paramount to 
creating TEBVs.  Although several cell sources were discussed in this section, the perfect 
cell source is one that is autologous, can be expanded quickly and easily in vitro, and can 
respond to both mechanical and biochemical stimuli [64,65]. 
1.8.3 Importance of Mechanical, Chemical, and Biological Stimulation 
 A blood vessel exists in a complex environment that involves pulsatile pressure 
and flow, cyclic wall deformations, and fluid shear stress.  Some blood vessels (i.e. 
coronary arteries) even experience bending, twisting, and stretching because they are 
located on the beating heart.  The cellular components of blood vessels, ECs and SMCs, 
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are capable of reacting to these stresses and strains in order to preserve homeostasis.  For 
example, SMCs require a certain amount of cyclic strain to maintain its contractile 
phenotype otherwise they will transition into a more synthetic phenotype, which could 
negatively affect normal vessel function.  Additionally, mechanical forces are necessary 
for remodeling and strengthening of both native blood vessels and TEBVs [65]. 
1.8.4 Bioreactors 
 According to Langer and Vicanti, tissue engineering is the amalgamation of 
engineering principles and life sciences used to create biological substitutes that serve to 
replenish, enhance, or conserve tissue functionality [67].  However, tissue-engineering 
products (i.e. TEBVs) achievable in the lab need to be scaled up for mass production in 
ways that are reproducible, safe, and economical [68].  Thus, the development of 
bioreactors remains a critical requirement for reaching mass production.   
The first two components of the classical tissue engineering paradigm, cell 
cultivation and cell seeding onto scaffolds were mentioned section 1.8.1 and 1.8.2, have 
already been discussed.  The final step in the tissue-engineering paradigm involves the 
conditioning of these TEBVs, which provides the necessary mechanical, chemical, and 
biological stimuli mentioned in section 1.8.3.  A bioreactor grants the researcher the 
ability to control culture conditions needed to induce specific cellular and tissue 
responses in vitro as opposed to in vivo tissue regeneration.  This aspect makes 
bioreactors a coveted tool for tissue engineering and regenerative medicine.  For vascular 
tissue engineering in particular, pulsatile perfusion bioreactors are the most suitable for 
developing TEBVs and other cardiovascular tissues [68]. 
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Recall that vascular cells (i.e. ECs and SMCs) experience pulsatile physical forces 
present throughout development and adulthood, which can be achieved in vitro using 
pulsatile perfusion systems.  Niklason and her lab introduced the first vascular perfusion 
system by transmitting pulsatile flow to individual reactors each containing one TEBV 
[69].  This seminal bioreactor can be found in Figure 12 below. 
 
Figure 12. First vascular perfusion system developed by Niklason and her lab12 
This bioreactor output pressures up to 270±30 mmHg, stroke volumes ranging from 0-10 
mL/stroke, and variable pulse rate between 60 and 165 beats/min.  Niklason et al were 
able to condition tubular, biodegradable scaffolds containing bovine vascular cells into 
physiological blood vessels by using the bioreactor in Figure 12.  These vessels had 
better mechanical strength, elevated collagen deposition, and improved contractility when 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
12 Niklason, L. E. (1999). Functional Arteries Grown in Vitro. Science, 284(5413), 489-493. 
doi:10.1126/science.284.5413.489 
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exposed to pharmaceutical drugs.   
Hoerstrup et al also created an innovative pulse duplicator system used for 
conditioning tissue-engineered heart valves and small diameter vascular grafts.  An air 
pump was used to displace an elastic membrane causing a pulsatile flow of media 
through biodegradable polymeric scaffolds seeded with vascular fibroblasts and ECs 
[70].  Using a similar concept, Engbers-Buijtenhuijs et al controlled shear rate, systolic 
and diastolic pressure, and pressure waveforms using a pulsatile flow system.  They were 
able to culture SMCs in porous tubular scaffolds by inducing an environment similar to 
the one experienced by the human carotid artery [71].   
Current bioreactor designs push towards manual feedback systems that can 
control pulsatile pressure and flow waveforms, but are not entirely physiological.  
Hildebrand et al explored the impact waveforms had on biologically active heart valves 
by developing a novel system that could automatically alter pressure and flow waveforms 
over the course of their study.  Furthermore, Mol et al created a novel bioreactor that 
could imitate the diastolic phase of the cardiac cycle.  They could apply pressure 
differences across tissue engineered heart valve leaflets producing variable strains across 
the leaflets [72]. 
Bioreactors allow researchers to accurately control the in vitro environment 
experienced by TEBVs and other tissues providing a better understanding of how 
mechanical, chemical, and biological stimuli impact tissue functionality.  Unfortunately, 
these bioreactors do not possess all of the necessary physiological stimuli resulting in 
tissues that display inferior or incomplete features compared to their native counterparts.  
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However, bioreactors are becoming more refined and future bioreactor models could be 
used to mass produce clinically relevant tissue engineered constructs.  Another pressing 
issue regarding bioreactor design lies with the complexities of different tissue types; a 
bioreactor could be beneficial for one tissue type and ineffective for another, so future 
bioreactors should be able to condition various tissue types.  Overall, bioreactor design 
and studies promote the continued collaboration between biologists and engineers who 
seek to understand the intricacies of physiology and pathology and its impact on tissue 
functionality [65]. 
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Chapter Two: Normotensive and Hypertensive FlexCell® 
Studies 
2.1 Introduction 
 In order to develop an appropriate treatment paradigm for patients with essential 
hypertension, a pathological model should be designed and studied at the cellular level, 
especially the interaction between ECs, SMCs, and the arterial ECM.  As mentioned in 
the introduction, ECs on the luminal surface of the arteries experience mechanical stimuli 
first, so elucidating their response to elevated pressure levels is vital for proper diagnosis 
and treatment of essential hypertension.  To do this, ECs were subjected to both 
normotensive and hypertensive transmural pressures to study how their cell-cell and cell-
ECM interactions are affected by one form of mechanical stimuli.   
 Naturally, the next step would be to study the vasoregulatory interaction between 
ECs and SMCs.  The initial mechanical stimuli leads to the secretion of bioactive 
molecules synthesized by ECs, which interact with underlying SMCs leading to either 
vasoconstriction or vasodilation.  Both ECs and SMCs were subjected to normotensive 
and hypertensive transmural pressures to fully explicate their vasoregulatory response to 
normal and inimical pressure conditions. 
2.2 Materials and Methods 
2.2.1 Media Preparation 
 Lonza’s EGM™-2 BulletKit™ was used to prepare 500 mL endothelial cell 
growth media.  Upon the manufacturer’s instructions, the basal media was vacuum 
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filtered into a sterile 1000 mL reagent bottle inside of a biosafety cabinet.  Next, 
additional growth factors listed in the table below were vacuum filtered into the basal 
media at the manufacturer’s recommended volumes.  The media bottle was covered in 
aluminum foil due to light sensitivity and stored at 4ºC.  A list of the media components 
with corresponding volumes can be found in Table 1 below. 
Media 
Components Volume 
EC Basal Media 500 mL 
Fetal Bovine 
Serum  10 mL 
hFGF 2 mL 
VEGF 500 µL 
R3-IGF-1 500 µL 
Ascorbic Acid 500 µL 
hEGF 500 µL 
GA-1000 500 µL 
Heparin 500 µL 
Hydrocortisone 200 µL 
Table 1. EC Media Components and Volumes 
500 mL of Human smooth muscle cell (hSMC) media was prepared by adding 10% fetal 
bovine serum and 1% antibiotic/antimycotic to 450 mL of Lonza’s Dulbecco’s Modified 
Eagle’s Media.  All components of the media were vacuum filtered into a sterile 1000 mL 
reagent bottle inside of a biosafety cabinet.  The media bottle was stored in a refrigerator 
at 4ºC.  A list of each media component with corresponding volumes can be found in 
Table 2 below. 
Media 
Components Volume 
DMEM 225 mL 
10% FBS 25 mL 
1% Ab/Am 2.5 mL 
Table 2. SMC Media Components and Volumes 
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2.2.2 hAEC Culture and Seeding onto BioFlex® Culture Plates 
Vials containing about 1 million passage 4 human aortic endothelial cells 
(hAECs) from Lonza were retrieved from storage in liquid nitrogen.  The vials were 
thawed quickly in a 37ºC water bath with gentle agitation until the ice crystals 
disappeared.  The cells were then pipetted onto a CELLSTAR™ T75 culture flask per 
manufacturer’s recommended seeding density of 5,000!"##$!"! .  These cells were cultured for 
a total of 4 days where the media was changed every 2 days.  After the 4-day culture 
period, the media was aspirated, the cells were rinsed using 1X sterile PBS, and detached 
from each flask by adding 4 mL of trypsin/EDTA and incubating the flask at 37ºC for 5 
minutes.  In order to counteract the effects of the trypsin/EDTA, 10 mL of endothelial 
cell media was added to each flask and the flasks were examined under the microscope to 
check for appropriate cell detachment.  The flask contents of each flask were then 
transferred to a 15 mL conical tube and centrifuged at 1000 rpm for 6 minutes.  After 
centrifugation, the media was aspirated from each conical tube leaving behind an 
endothelial cell pellet, which was resuspended by adding 2 mL of media to each flask.  
The total amount of viable cells was acquired using a cell scepter and a Luna cell counter, 
which typically yielded a density of about 1.5x104 !"##$!"  or about 3x106 cells.  About 
750,000 cells were evenly pipetted onto BioFlex® 6-well culture plates (about 125,000 
cells per well).  An additional 2 mL of media was added to each well and the plates were 
incubated at 37ºC and 5% CO2 overnight to ensure cell attachment.  The leftover cells 
were either seeded onto another T175 flask or frozen down for storage in liquid nitrogen.  
It is important to note that the bottom of each BioFlex® culture plate is an elastic silicone 
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membrane that can deform under applied pressure, which simulates an arterial wall.  
Furthermore, each silicone membrane comes pre-coated with pronectin to help with cell 
adhesion. 
2.2.3 hSMC Culture and Seeding onto BioFlex® Culture Plates 
Vials containing 1 mL of 3x106 passage 4 hSMCs was obtained from storage in 
liquid nitrogen and quickly thawed in a 37ºC water bath.  The vial was then sprayed 
down with 70% ethanol and placed under sterile conditions within the biosafety cabinet.  
The 1 mL cell solution was transferred into a 15 mL conical tube containing 10 mL of 
hSMC media and centrifuged at 1000 rpm for 6 minutes.  Immediately following 
centrifugation, the supernatant was aspirated and the cell pellet was resuspended using 2 
mL of media inside the biosafety hood.  The 2 mL cell solution was pipetted into a 
CELLSTAR® T175 flask already filled with 15 mL of hSMC media maintaining the 
manufacturer’s recommended cell seeding density of 10,000!"##$!"! .  The media within each 
flask was changed every 2 days.  Following the culture period, the hSMCs were detached 
from the culture flask using trypsin/EDTA and counted using a cell scepter and Luna cell 
counter.  Typically 30,000!"##$!"  or 5.5x106 cells were obtained from each flask.  About 
250,000 cells were evenly pipetted into the wells of pronectin-coated BioFlex® 6-well 
culture plates already containing attached hAECs and 2 mL of hAEC media.  The 
detachment, counting, and seeding procedures of hSMCs are the same as hAECs, which 
is previously described in section 2.2.2.  The leftover cells were either seeded onto 
another T175 flask or frozen down for storage in liquid nitrogen.  In order to maintain 
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hAECs and hSMCs on the BioFlex® culture plates, 2 mL of SMC media was added to 
each well upholding a 1-to-1 EC-SMC media ratio.  These BioFlex® culture plates were 
incubated overnight at 37ºC and 5% CO2 to ensure hSMC attachment. 
2.2.4 FlexCell® Set-Up  
 Transmural pressure was controlled using the FlexCell® FX-5000 Compression 
System.  Two BioFlex® well plates containing adhered hAECs will be placed onto the 
FlexCell® compression baseplate for normotensive and hypertensive studies.  Two 
empty BioFlex® well plates will be placed onto the two other empty positions on the 
baseplate in order for the system to function properly.  The baseplate will then be 
carefully sandwiched in between two transparent acrylic windows.  The whole assembly 
will be placed into a special clamping system provided by FlexCell® Inc.  All eight wing 
nuts are tightened by hand until they are finger tight.  The assembly will then be 
transferred into an incubator.  The blue ¼-inch Flex-In tubing extending from the 
baseplate will clip into its corresponding ¼-inch Flex-In tubing that is connected to an air 
source.  The yellow 3/8-inch Flex-Out tubing extending from the baseplate will connect 
to its corresponding yellow 3/8-inch Flex-Out tubing that is linked to the FlexCell® 
computer system, which monitors the amount of pressure experienced inside the wells of 
the BioPress® culture plates.  Refer to Figure 13 below to see the complete set-up. 
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Figure 13. FlexCell® FX-5000 Compression System Set-Up 
2.2.5 Conditioning Waveforms 
In order to control the pressure using the FlexCell® FX-5000 Compression 
System, pressure waveforms have to be developed using Excel by relating the percent 
elongation experienced by each BioPress® culture plate to specific time points of the 
cardiac cycle.  The cardiac cycle lasts a total of 0.8 seconds where systole lasts 0.27 
seconds and diastole lasts for 0.53 seconds.  Each waveform is modeled after the pressure 
profile generated during a cardiac cycle as seen in the Wigger’s diagram below. 
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Figure 14. Wigger’s Diagram showing the pressure profile of a single cardiac cycle13 
Dr. Jason Schulte, an alumnus from our lab, developed a 40 mmHg and an 80 mmHg 
pressure profile using Excel, which were uploaded into the FlexCell® computer program.  
All waveforms were created using Excel by relating percent elongation to specific time 
points in the cardiac cycle.  Additionally, a LabVIEW program was used to monitor the 
pressure generated by the FlexCell® compression system in real time.  The waveform 
portrayed on the FlexCell® computer program and LabVIEW program for both 40 
mmHg and 80 mmHg can be seen in Figure 15 and Figure 16 below.   
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
13 Image taken from http://www.diagrama.xyz/wiggers-diagram/ 
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Figure 15. FlexCell® and LabVIEW Programs at 40 mmHg 
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Figure 16. FlexCell® and LabVIEW Programs at 80 mmHg 
2.2.6 Normotensive Waveform  
 Similar to the 40 mmHg and 80 mmHg waveform, Dr. Schulte created a 
normotensive waveform with a peak systolic pressure at 120 mmHg on Excel by relating 
the percent elongation of the silicone membrane in each well to specific time points on 
the cardiac cycle in increments of 12.5 milliseconds, which can be seen in Table 3 below. 
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Time (t) 
[ms] 
Force (F) 
[lbf] 
0 0 
12.5 0 
25 0 
37.5 0 
50 0 
62.5 0 
75 0 
87.5 0 
100 0 
112.5 0 
125 0 
137.5 0.151000477 
150 0.6667821 
162.5 1.426215017 
175 2.466638112 
187.5 2.694467987 
200 2.922297862 
212.5 2.97925533 
225 3.036212799 
237.5 3.093170268 
250 3.127344749 
262.5 3.134939078 
275 3.150127737 
287.5 3.142533407 
300 3.134939078 
312.5 3.11975042 
325 3.096967432 
337.5 3.058995787 
350 3.013429812 
362.5 2.945080849 
375 2.843823137 
387.5 2.742565425 
400 2.641307713 
412.5 2.413477838 
425 2.185647963 
437.5 1.729988214 
450 1.274328464 
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462.5 0.666782131 
475 0.059235798 
487.5 0 
500 0 
512.5 0 
525 0 
537.5 0 
550 0 
562.5 0 
575 0 
587.5 0 
600 0 
612.5 0 
625 0 
637.5 0 
650 0 
662.5 0 
675 0 
687.5 0 
700 0 
712.5 0 
725 0 
737.5 0 
750 0 
762.5 0 
775 0 
787.5 0 
800 0 
Table 3. Normotensive Waveform Relating Time Points in the Cardiac Cycle to Force 
Table 3 was uploaded to the FlexCell® program, which converted the percent elongation 
values to force in units of force-lbs or pressure in units of kPa.  The 120 mmHg (i.e. 
normotensive) pressure profile generated by the FlexCell® program can be seen in 
Figure 17 below. 
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Figure 17. Normotensive Waveform in Flexcell® Program 
Again, the actual pressure experienced in the wells of the BioPress® plates was 
monitored using LabVIEW as seen in Figure 18 below. 
 
Figure 18. Normotensive LabView® Pressure Waveform 
2.2.7 Hypertensive Waveform 
 Using a similar approach to that of Dr. Schulte, a 140 mmHg waveform was 
created on Excel to emulate hypertensive conditions inside the wells of the BioPress® 
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culture plates.  First, a table that related known pressure values to corresponding time 
points during a single cardiac cycle was created in Excel.  The cardiac cycle, 0.8 seconds 
long, was divided into increments of 12.5 milliseconds with the first time point of 0 
seconds corresponding to the beginning of systole.  Known cardiac pressures and 
corresponding time points were estimated using the Wigger’s diagram seen in Figure 14 
above.  An Excel cubic spline interpolation function was used to fill in the missing 
pressure values for the other time points on the table.  After creating the initial table, 
pressure values were converted to force using this equation: 𝑃!"# = 5.65 ∗ 𝐹𝑜𝑟𝑐𝑒!"# /(𝐷!!!).  The Excel table can be seen in Table 4 below with the time points of known 
pressure values highlighted in yellow. 
Time (t) 
[ms] 
Force (F) 
[lbf] 
0 0 
12.5 1.53753046 
25 2.37355479 
37.5 2.616589622 
50 2.841630701 
62.5 3.046890567 
75 3.230581763 
87.5 3.390916829 
100 3.526108305 
112.5 3.634368734 
125 3.713910656 
137.5 3.762946613 
150 3.779689145 
162.5 3.767922768 
175 3.733819711 
187.5 3.679174086 
200 3.605780003 
212.5 3.515431572 
225 3.409922905 
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237.5 3.291048112 
250 3.160601305 
262.5 3.020376593 
275 2.7911253 
287.5 2.412340476 
300 1.913928828 
312.5 1.325797062 
325 0.677851884 
337.5 0 
350 0 
362.5 0 
375 0 
387.5 0 
400 0 
412.5 0 
425 0 
437.5 0 
450 0 
462.5 0 
475 0 
487.5 0 
500 0 
512.5 0 
525 0 
537.5 0 
550 0 
562.5 0 
575 0 
587.5 0 
600 0 
612.5 0 
625 0 
637.5 0 
650 0 
662.5 0 
675 0 
687.5 0 
700 0 
712.5 0.105643302 
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725 0.211286603 
737.5 0.201426562 
750 0.174663592 
762.5 0.135223426 
775 0.087331796 
787.5 0.035214434 
800 0 
Table 4. Hypertensive Waveform Relating Time Points in the Cardiac Cycle to Force 
The Excel table was uploaded to the FlexCell® computer program, which converted the 
percent elongation to force in units of force-pounds.  The 140 mmHg waveform 
generated by the FlexCell® program can be seen in Figure 19 below. 
 
Figure 19. Hypertensive Waveform generated in FlexCell® Program 
LabVIEW was used to monitor that the peak pressure achieved was 140 mmHg, which 
can be seen in Figure 20 below. 
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Figure 20. Hypertensive Waveform as seen in LabView® 
2.2.8 Normotensive Monoculture Study  
ECs were cultured on a T75 flask and maintained for a couple of days using the 
cell culture protocol mentioned above.  Upon confluency, the ECs were detached, 
counted, and seeded onto two BioPress® 6-well plates as described above.  Overnight 
incubation at 37ºC and 5% CO2 ensured that the ECs adhered to the flexible silicone 
membrane pre-coated with pronectin.  On the next day, two BioPress® plates containing 
ECs were loaded onto the FlexCell® system described in section 2.2.4.  These plates 
were conditioned at 40 mmHg for 24 hours; on the next day, the pressure was increased 
to 80 mmHg for another 24 hours.  After the aforementioned conditioning steps, the two 
BioPress® compression plates were subjected to normotensive pressure conditions (peak 
systolic pressure of 120 mmHg and peak diastolic pressure of 80 mmHg) using the 
waveform in section 2.2.6 for a total of four days.  The media would be changed every 
two days. 
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2.2.9 Hypertensive Monoculture Study 
 Similar to the normotensive monoculture study, ECs were cultured in a 
T75 flask and maintained for a couple of days using procedures described in section 
2.2.2.  When confluent, the ECs were detached, counted, and seeded onto two BioPress® 
6-well plates also found in section 2.2.2.  Overnight incubation at 37ºC and 5% CO2 
ensured that the ECs adhered to the flexible silicone membrane pre-coated with 
pronectin.  On the next day, two BioPress® plates containing ECs were loaded onto the 
FlexCell® system described in section 2.2.4.  These plates were conditioned at 40 mmHg 
for 24 hours; on the next day, the pressure was increased to 80 mmHg for another 24 
hours.  After the aforementioned conditioning steps, the plates would be unloaded and the 
media would be changed.  Next, the two BioPress® compression plates were subjected to 
hypertensive pressure conditions (peak systolic pressure of 140 mmHg and peak diastolic 
pressure of 90 mmHg) using the waveform in section 2.2.7 for a total of four days.  The 
media would be changed every two days. 
2.2.10 Normotensive Co-Culture Study 
 For this study, ECs were cultured in a T75 flask and sustained for a couple of 
days using cell culture methods described in section 2.2.2.  hSMCs were simultaneously 
cultured in a T175 flask using cell culture methods mentioned in section 2.2.3.  Upon 
confluency, the ECs were detached, counted, and seeded onto two BioPress® 6-well 
plates also found in section 2.2.2.  Overnight incubation at 37ºC and 5% CO2 ensured that 
the ECs adhered to the flexible silicone membrane pre-coated with pronectin.  On the 
next day, the hSMCs were similarly detached, counted, and seeded onto the two 
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BioPress® plates with the adhered ECs.  Overnight incubation at 37ºC and 5% CO2 
ensured that the hSMCs had time adhere to the bottom of each wells.  The media was 
changed the next day using a 1:1 ratio of EC media and SMC media (2 mL EC media to 2 
mL SMC media).  After changing the media, the two BioPress® plates containing ECs 
were loaded onto the FlexCell® system described in section 2.2.4.  Like the monoculture 
studies, the plates were conditioned at 40 mmHg for 24 hours and at 80 mmHg for 
another 24 hours.  After the conditioning steps, the plates would be unloaded and the 
media would be changed.  Once fresh media was added to each well, the two BioPress® 
plates were loaded once again onto the FlexCell® system and would be subjected to 
normotensive pressure conditions (peak systolic pressure of 120 mmHg and peak 
diastolic pressure of 80 mmHg) using the waveform in section 2.2.7 for a total of four 
days.  The media would be changed every two days. 
2.2.11 Hypertensive Co-Culture Study 
As with the normotensive co-culture study, ECs were cultured in a T75 flask and 
sustained for a couple of days using cell culture methods described in section 2.2.2.  
hSMCs were simultaneously cultured in a T175 flask using cell culture methods 
mentioned in section 2.2.3.  Upon confluency, the ECs were detached, counted, and 
seeded onto two BioPress® 6-well plates also found in section 2.2.2.  Overnight 
incubation at 37ºC and 5% CO2 ensured that the ECs adhered to the flexible silicone 
membrane pre-coated with pronectin.  On the next day, the hSMCs were similarly 
detached, counted, and seeded onto the two BioPress® plates with the adhered ECs.  
Overnight incubation at 37ºC and 5% CO2 ensured that the hSMCs had time adhere to the 
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bottom of each wells.  The media was changed the next day using a 1:1 ratio of EC media 
and SMC media (2 mL EC media to 2 mL SMC media).  After changing the media, the 
two BioPress® plates containing ECs were loaded onto the FlexCell® system described 
in section 2.2.4.  Like the previous FlexCell® studies, the plates were conditioned at 40 
mmHg for 24 hours and at 80 mmHg for another 24 hours.  After the conditioning steps, 
the plates would be unloaded and the media would be changed.  Once fresh media was 
added to each well, the two BioPress® plates were loaded once again onto the FlexCell® 
system and would be subjected to normotensive pressure conditions (peak systolic 
pressure of 140 mmHg and peak diastolic pressure of 90 mmHg) using the waveform in 
section 2.2.7 for a total of four days.  The media would be changed every two days. 
2.2.12 Live Dead Assay  
 One well of a single BioFlex® plate from each FlexCell® study was used for a 
live-dead assay.  Under sterile conditions inside of the biosafety cabinet, 0.5 µL of 
Calcein AM and 2 µL of Ethidium homodimer-1 were added to 1 mL of sterile DPBS to 
create the live-dead solution; the final solution was mixed to ensure homogeneity.  The 
media was aspirated from the well and the well was rinsed with warm, sterile 1X PBS.  
Next, the 1 mL live-dead solution was added to the well and the culture plate was 
covered and incubated in the dark for 20 minutes at 37ºC and 5% CO2.  The well was 
imaged using a fluorescent microscope. 
2.2.13 Immunofluorescence 
 After the completion of each FlexCell® study, one BioFlex® plate from each 
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study was dedicated to immunofluorescence in order to detect the expression of specific 
proteins.  First, the media is removed and each well is rinsed with 2 mL of warm 1X PB 
for 5 minutes.  The PBS was removed and the cells in each well were fixed with 4% 
warm para-formaldehyde (pFA) for 20 minutes at room temperature.  After 20 minutes, 
the pFA was removed and the wells were rinsed with 2 mL of 1X PBS three times for 5 
minutes each rinse.  Following the rinse steps, 0.2% Triton was added to each well for 10 
minutes to permeabilize the cells.  The triton was removed after 10 minutes and the cells 
were blocked using 5% BSA and 0.05% Triton in PBS for 2 hours.  When blocking was 
complete, primary antibodies diluted in a blocking solution (1 mL PBS:1 mL blocking 
agent) was added to each well and left overnight at 4 ºC.  For the monoculture studies, 
three primary antibodies were used: focal adhesion kinase (FAK), Integrin β1, and VE-
cadherin.  Two wells would be stained by one primary antibody solution; for example, 1 
mL of the FAK antibody solution would be added to each of the two wells.  For the co-
culture studies, three primary antibodies were used: endothelial nitric oxide synthase 
(eNOS), endothelin-1, and angiotensin II.  Similarly, two wells would be stained by one 
primary antibody solution; for example, 1 mL of the eNOS antibody solution would be 
added to each of the two wells.  On the next day, the antibody solutions in each well were 
removed and saved in labeled microcentrifuge tubes.  Each microcentrifuge tube can be 
stored in the freezer and reused for future immunofluorescence studies that require the 
same antibodies.  The wells were rinsed three times with warm 1X PBS for 5 minutes 
each rinse cycle.  During the rinse steps, 4 µL of secondary Alexa Fluor 488 antibodies 
was added 1-to-1 PBS-blocking agent solution.  After the final rinse cycle, 1 mL of the 
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secondary antibody solution was added to each well and was incubated for 1 hour in the 
dark and at room temperature.  When the hour was up, the secondary antibody solution 
was removed and each well was rinsed one last time with 1X PBS.  Finally, the wells 
were mounted using a DAPI solution and imaged using a fluorescence microscope. 
2.2.14 Protein Extraction 
 Proteins were extracted from the remaining 5 wells of the BioPress® plate used in 
the live-dead assay.  Under non-sterile conditions, the media was aspirated from these 
wells and 2 mL of warm 1X PBS was used to rinse each well for 5 minutes.  After two 
rinse cycles, 1 mL of cold RIPA buffer was added to each well and the BioPress® plate 
was incubated on ice for 5 minutes with occasional swirling.  After the incubation period, 
a cell scraper was used to detach the lysate from the bottom of each well.  The lysate in 
RIPA buffer was transferred to 1.5 mL microcentrifuge tubes; the tubes were incubated in 
ice for 5 minutes with occasional sonication.  Next, the microcentrifuge tubes containing 
the lysate in RIPA buffer was centrifuged for 15 minutes at 14,000 rcf and at 4ºC.  After 
centrifugation, the supernatant was transferred to a new vial and the samples were stored 
in the freezer until proteins samples were needed for BCA assays and western blots. 
2.2.15 BCA Assay 
 The Pierce™ BCA protein assay kit was used to quantify the amount of available 
protein and the amount of protein sample and electrophoresis buffer needed for a western 
blot.  First, the BCA working reagent was prepared by mixing 50 parts of reagent A with 
1 part of reagent B provided in the kit.  Next, protein standards were prepared in 
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microcentrifuge tubes using a standard stock solution of albumin (2 mg/mL) and RIPA 
buffer as a diluent.  Table 5 shows the nine standards and the volume of each solution 
used to create the standard per manufacturer’s instructions. 
Vial Volume Diluent  
(ul) 
Volume & Source of 
BSA (uL) 
Final BSA Concentration  
(ug/ml) 
A 0 300 of stock 2,000 
B 125 375 of stock 1,500 
C 325 325 of stock 1,000 
D 175 175 of vial B dilution 750 
E 325 325 of vial C dilution 500 
F 325 325 of vial E dilution 250 
G 325 325 of vial F dilution 125 
H 400 100 of vial G 
dilution 
25 
I 400 0 0 = blank 
Table 5. BCA Standards 
After the working reagent and standards were prepared, 10 µL of each standard were 
added in duplicates to the first two rows of a 96-well plate.  Similarly, 10 µL of each 
protein sample extracted in section 2.2.14 was added in duplicates to another two rows on 
the 96-well plate.  Finally, 200 µL of the working reagent was added to each well 
containing standards and protein samples; note that this step should be completed in the 
dark due to the reaction’s sensitivity to light.  The plate was covered, wrapped in 
aluminum foil, and incubated for 60 minutes at 37ºC.  At the end of the incubation 
period, the plate was cooled to room temperature and the absorbance was measured at 
562 nm using a BioTek® FLx800 fluorescence reader. 
2.2.16 Western Blot Protocol 
 Using the standard curve generated using the BCA assay described in Section 
2.2.15, the sample volume necessary to obtain 20 µg of protein was calculated.  The 
	  	   87	  
correct amount of protein samples were pipetted into microcentrifuge tubes and diluted 
with the appropriate reducing buffer to bring the volume up to 43.25 µL.  Subsequently, 
1.75 µL of β-mercaptoethanol (βME) was added to protein sample and reducing buffer 
solution making the final volume 50 µL.  Electrophoresis and transfer steps ran at 
standard conditions.  For the monoculture studies, the blots were tagged with three 
primary antibodies: focal adhesion kinase (FAK), Integrin β1, and VE-cadherin.  For the 
co-culture studies, the blots were tagged with three primary antibodies: endothelial nitric 
oxide synthase (eNOS), endothelin-1, and angiotensin II.  These primary antibodies were 
detected using a secondary mouse/rabbit antibody and other reagents provided in the 
Roche BM Chemiluminescence Western Blotting Kit.  These blots were imaged using the 
BioRad ChemiDoc™ MP System and bands were analyzed for relative intensity and 
molecular weight on the accompanying imaging software. 
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2.3 Results 
2.3.1 Live Dead Assay 
 
Figure 21. Normotensive and Hypertensive Live-Dead Images from Mono-Culture Studies 
 
Figure 22. Normotensive and Hypertensive Live-Dead Images from Co-Culture Studies 
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2.3.2 Immunofluorescence 
 
Figure 23. Normotensive and Hypertensive DAPI-Immunofluorescence Overlay from Mono-Culture Study 
at 10x Magnification 
 
Figure 24. Normotensive and Hypertensive DAPI-Immunofluorescence Overlay from Mono-Culture Study 
at 20x Magnification 
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Figure 25. Normotensive and Hypertensive DAPI-Immunofluorescence Overlay from Co-Culture Study at 
10x Magnification 
 
Figure 26. Normotensive and Hypertensive DAPI-Immunofluorescence Overlay from Co-Culture Study at 
20x Magnification 
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2.3.3 Western Blots 
 
Figure 27. VE-Cadherin Expression from 120 mmHg EC Mono-Culture Study 
 
Figure 28. VE-Cadherin Expression from 140 mmHg EC Mono-Culture Study 
Pressure 
Level 
Mean Band 
Intensity 
Standard 
Deviation Variance 
120 mmHg 31.42 0.46 0.42 
140 mmHg  4.85 0.57 0.66 
P-Value 0.001     
Table 6. Statistical Analysis of VE-Cadherin Expression between120 mmHg and 140 mmHg Transmural 
Pressures 
 
Figure 29. VE-Cadherin Band Intensity Comparison between 120 mmHg and 140 mmHg EC Mono-
Culture Studies 
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Figure 30. Endothelin Expression from 120 mmHg EC-SMC Co-Culture Study 
 
Figure 31. Endothelin Expression from 140 EC-SMC Co-Culture Study 
Pressure 
Level 
Mean Band 
Intensity 
Standard 
Deviation Variance 
120 mmHg 2.06 0.50 0.50 
140 mmHg  6.33 3.86 22.40 
P-Value 0.26 
  Table 7. Statistical Analysis of Endothelin Expression between120 mmHg and 140 mmHg Transmural 
Pressures 
 
Figure 32. Endothelin Band Intensity Comparison between 120 mmHg and 140 mmHg EC-SMC Co-
Culture Studies 
 
Figure 33. Angiotensin Expression from 120 mmHg EC-SMC Co-Culture Study 
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Figure 34. Angiotensin Expression from 140 mmHg EC-SMC Co-Culture Study 
Pressure 
Level 
Mean Band 
Intensity 
Standard 
Deviation Variance 
120 mmHg 3.94 0.17 0.05 
140 mmHg  4.07 1.68 4.26 
P-Value 0.92   Table 8. Statistical Analysis of Angiotensin Expression between120 mmHg and 140 mmHg Transmural 
Pressures 
 
Figure 35. Angiotensin Band Intensity Comparison between 120 mmHg and 140 mmHg EC-SMC Co-
Culture Studies  
2.4 Discussion 
2.4.1 Live-Dead Images from Monoculture and Co-Culture Studies  
As seen in Figure 21, ECs were able to survive at both 120 mmHg and 140 
mmHg transmural pressures with minimal cell death.  However, the ECs assumed a more 
globular phenotype at both transmural pressures.  Furthermore, the ECs were not 
confluent and homogeneously aligned like they would be in an artery of the human body, 
which could be attributed to the lack of cell-cell interaction and flow-induced shear 
stress. 
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From the Live-Dead images in Figure 22, both ECs and SMCs survived at both 
normotensive and hypertensive transmural pressures.  The SMC-EC co-cultures boasted 
better confluence and homogeneity compared to the EC monocultures.  However, the cell 
alignment of both cell types remained sporadic.  Furthermore, ECs remained globular and 
qualitatively, the total cell count for ECs seemed marginal compared to the SMCs, 
especially in the 140-mmHg co-culture.  This might indicate that proliferation rates for 
hSMCs increases in response to elevated pressure conditions, but these is merely a 
qualitative observation and total cell count was not quantified in these studies. 
2.4.2 Immunofluorescence Images from Monoculture and Co-Culture Studies 
All of the primary adhesion proteins were expressed at the 120-mmHg transmural 
pressure as seen in the top three images of Figure 23 and Figure 24.  At the 140-mmHg 
transmural pressure level, FAK and VE-cadherin were expressed, but integrin β1 was not.  
This observation could mean that normal EC adhesion to ECM proteins like fibronectin 
may be compromised leading to cell detachment during hypertension.  Integrin β1 
dysfunction could negatively impact FAK and VE-cadherin functionality downstream in 
the signal transduction pathway.  Overall, the fluorescent images exemplify EC cell-cell 
adherens junctions denoted by the visible cell extensions between cells.  However, EC 
confluence was wanting like in the initial live-dead stains.   
 As seen in the immunofluorescence images of Figure 25 and Figure 26, wells 
from both co-culture studies were stained for important vasoregulatory molecules: eNOS, 
endothelin-1, and angiotensin-II.  Both the 120 mmHg and 140 mmHg co-culture studies 
expressed all three vasoregulatory proteins.  However, the ECs and SMCs subjected to 
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140 mmHg qualitatively displayed reduced levels of eNOS expression.  The expression 
can still be seen in the image, but it is not as vivid especially at 20x magnification.  
Recall that eNOS is normally active in ECs and produces NO, which is an important 
vasodilatory agent.  Initially, eNOS activity increases in response to hypertension, but 
prolonged exposure to elevated pressure levels will impair eNOS functionality effectively 
reducing NO availability.  Thus, less eNOS expression on ECs can be expected during 
essential hypertension.  Furthermore, angiotensin and endothelin expression were seen in 
both the normotensive and hypertensive co-culture studies.  Endothelin and angiotensin 
are active at normal levels under physiological conditions, but both can exacerbate EC 
dysfunction when exposed to hypertension.  As stated in literature, endothelin levels in 
plasma remain constant during hypertension, but their activity becomes elevated.  
Angiotensin can either stimulate NADPH oxidase activity or promote NO production.  
Thus, western blots were used to quantify protein expression in order to truly elucidate 
the effect of hypertension on cell adhesion and vasoregulation. 
2.4.3 Western Blots from Monoculture and Co-Culture Studies 
 Western blots were conducted for each of the three adhesion proteins from both 
pressure studies, but only VE-cadherin produced distinct bands as seen in Figure 27 and 
Figure 28.  From literature and the company’s website, the estimated molecular weight 
for VE-cadherin was around 87 kDa, but bands could be detected anywhere between 75 
kDa and 115 kDa.  By measuring band intensity using the BioRad® western blot 
software, the average normalized band intensity was calculated in Excel, which can be 
seen in Table 6.  The standard deviation was calculated and used to generate the error 
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bars seen in Figure 29; the variance was calculated to verify that the two test groups did 
not have the same variance.  Finally, a two-tailed t-test was performed to check whether a 
significant difference exists between the two test groups.  The p-value was 0.001, which 
is less than 0.05, so there is a significant decrease in VE-cadherin expression for the 140-
mmHg transmural pressure condition.  The difference in VE-cadherin expression in terms 
of band intensity can be seen in Figure 29.  This finding establishes that EC cell-cell 
junctions become severely compromised in patients with hypertension.  Although 
integrin β1 did not show up in the western blots and its expression could not be 
quantified, the lack of integrin β1 fluorescence coupled with the significant decrease in 
VE-cadherin expression by ECs in the 140 mmHg monoculture studies is enough to 
conclude that hypertension impairs EC adhesion and compromises the activity of 
important adhesion proteins.  These findings not only support literature claims that 
hypertension-induced EC dysfunction is a direct result of elevated blood pressure 
conditions, but also elucidates some of the signaling molecules and associated signal 
transduction pathways that cause the dysfunction. 
 Western blots were also conducted for the three vasoregulatory proteins, but only 
endothelin and angiotensin produced distinct bands.  The bands for endothelin were seen 
at 48 kDa for both pressure conditions, which can be seen in Figure 30 and Figure 31; 
this matched the literature values listed on the company’s website.  Similar to VE-
cadherin, the band intensities obtained from the BioRad program were normalized and 
averaged for both normotensive and hypertensive co-culture studies, which can be found 
in Table 7.  The bar graph displayed in Figure 32 was generated using the normalized 
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average band intensity for each study.  Standard deviations were calculated and used to 
generate the error bars in the bar graph.  Finally, the variance was calculated to verify that 
the two variances were different, which is important in determining the type of t-test to 
choose.  Finally, a two-tailed t-test was used to determine if there was a significant 
difference in endothelin expression between the normotensive and hypertensive co-
culture studies.  As seen in Figure 32, there seems to be a significant increase in 
endothelin expression for the 140 mmHg co-culture study when compared to the 120 
mmHg co-culture study.  However, the p-value obtained from the t-test was 0.26, which 
is greater than 0.05 indicating that there was not a significant difference in endothelin 
expression.  Even though a significant difference was not established, the large increase 
in endothelin expression portrayed in the bar graph should be enough to contribute to EC 
dysfunction commonly linked with hypertension.  The fact that there was an increase at 
all supports literature claim that endothelin expression becomes elevated in patients with 
hypertension.  Even though eNOS bands were not detected in the wester blots, elevated 
endothelin expression could indirectly signify reduced NO levels and eNOS activity, 
since NO normally inhibits endothelin activity. 
Angiotensin bands were also detected below 75 kDa for both pressure studies as 
seen in Figure 33 and Figure 34; the company’s website and literature sources stated that 
a band should be detected around 45 kDa, but bands could be seen at 40, 45, 60 kDa 
depending on the degree of glycosylation.  Just like VE-cadherin and endothelin, the 
band intensities measured using the BioRad program were normalized and averaged in 
Excel and can be found in Table 8.  From the bar graph in Figure 35, there seemed to be 
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a slight increase in angiotensin expression for the 140 mmHg co-culture studies, but not 
enough to warrant significance.  A two-tailed t-test produced an extremely high p-value 
of 0.92, which was greater than 0.05 and confirms that there was no significant difference 
in angiotensin expression.  However, these results could be attributed to the discrepancies 
mentioned in literature.  The role angiotensin plays in hypertension remains equivocal, 
but the slight increase in angiotensin expression for the hypertensive conditions could 
hint that angiotensin levels and activity increases in response to hypertension.  Future 
studies need to be conducted to corroborate this claim. 
2.5 Conclusion 
 Essential hypertension begets EC dysfunction, but hypertension-induced EC 
dysfunction has not been fully characterized.  These FlexCell® studies confirmed that 
impaired cell adhesion and compromised vasoregulation are traits of EC dysfunction as a 
direct result of elevated blood pressure levels.  Futhermore, the results from these culture 
studies revealed some of the key proteins linked to EC dysfunction and provided theories 
as to how hypertension affects several signal transduction pathways associated with these 
proteins in relation to cell adhesion and interaction.  The FlexCell® is a great platform 
for studying the intricacies of hypertension and future studies should be conducted to 
further establish the link between hypertension and EC dysfunction. 
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Chapter 3: Bioreactor Model for Studying the Effect of 
Hypertension on Vascular Cells 
3.1 Introduction 
 The FlexCell® studies described in Chapter 2 exhibited how ECs and SMCs are 
impacted by elevated transmural pressures.  Although these FlexCell® studies elucidated 
several cellular responses to essential hypertension, transmural pressure was the only 
mechanical force investigated in these studies.  Furthermore, the FlexCell® studies 
confirmed that EC dysfunction and excessive SMC proliferation persists as a direct result 
of high blood pressure levels, but these studies failed to depict how high blood pressure 
levels affects the arterial ECM via adverse arterial remodeling.  Thus, a novel bioreactor 
model should be developed in order to fully characterize the pathophysiological response 
of both cells and arteries to elevated blood pressure levels and abnormal shear forces 
induced by fluid flow.  After designing a novel pathology model for hypertension, a 
preliminary study was conducted following the classic tissue-engineering paradigm 
where cells were initially cultured and seeded onto a decellularized arterial scaffold and 
the resulting TEBV was conditioned inside an bioreactor system except the blood 
pressure levels were elevated to mimic hypertension.  The results from this preliminary 
study validated that the pathology model worked and could be used to study hypertension 
as well as other vascular diseases, but the system as a whole needs to be improved before 
conducting future studies.  Additionally, this bioreactor system could also be tailored to 
produce functional TEBVs for clinical use in the future. 
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3.2 Materials and Methods 
3.2.1 Porcine Carotid Artery Preparation and Decellularization 
 Fresh porcine carotid arteries were obtained from the Snow Creek Meat 
Processing Plant located in Seneca, SC.  For initial cleaning, the arteries were soaked in 
an ice cold 0.9% saline solution.  Each carotid artery was cut to a length of about 5 cm 
long.  Additionally, any residual connective and fatty tissue found on the outside of the 
arteries were carefully cut.  Any holes and arterial branches were closed using sutures. 
After the initial artery preparation, a 0.1 M NaOH solution was made.  Three 
carotid arteries were placed into 50 mL conical tubes and 45 mL of the 0.1 M NaOH 
solution was added.  The conical tubes were incubated in a 37ºC water bath for 24 hours.  
After 24 hours of NaOH treatment, the arteries were transferred to a beaker filled with 
ddH2O and the beaker was placed on a shaker for 5 minutes.  The ddH2O was removed 
and fresh ddH2O was added to the beaker.  Again, the beaker was placed on a shaker for 
5 minutes.  The process was repeated until the pH of the rinsing ddH2O reached ~7.5.  
After the rinsing water was at a pH of 7.5, the arteries were transferred to a bottle 
containing 70% ethanol, which was placed on a shaker overnight at room temperature.  
The next day the arteries were transferred into an autoclaved large mouth media bottle 
inside the biosafety cabinet under sterile conditions.  The arteries were washed four times 
with sterile ddH2O for 15 minutes each wash.  After washing, the arteries were placed in 
0.1% paracetic acid added to 1X sterile PBS, which was at a pH of 7.  The bottle was 
capped and placed on an orbital shaker for 6 hours.  After 6 hours and under sterile 
conditions, the paracetic acid was removed and the tissues were rinsed with sterile ddH2O 
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for 1 hour with the sterile ddH2O changed every 15 minutes.  Finally, the arteries were 
rinsed 3 times with sterile 1X PBS for 10 minutes each rinse cycle on an orbital shaker.  
After the last rinse step, the arteries were stored in sterile 1X PBS with 1% 
antibiotic/antimycotic at 4ºC. 
3.2.2 hSMC Media Preparation and Culture 
 The same protocol from section 2.2.1 and section 2.2.3 was used to prepare the 
SMC media and culture the SMCs. 
3.2.3 Histological Process – Tissue Processing, Embedding, and Sectioning 
 The desired tissues were soaked in formalin for at least 24 hours.  After 24 hours, 
the cut tissues were removed from formalin and placed into tissue cassettes and properly 
labeled.  The cassettes were placed into the tissue processor and the processing program 
was run for 8 hours.   
Once tissue processing was complete, the tissues were removed from the cassettes 
and placed on a hot plate to melt away any residual paraffin.  A metal plate would be 
filled with paraffin and transferred over to a cold plate.  Immediately, the tissue was 
transferred to the bottom of the metal plate in the correct orientation.  The cassette would 
be fashioned on top of the metal plate and the construct would be topped off with 
paraffin.  The constructs were placed onto a large cooling plate to allow the paraffin to 
harden.  Once the paraffin hardened, the metal plates could be removed. 
Next, the cassettes with the tissue sample embedded in paraffin wax were 
attached to the microtome holder.  15 µm sections were cut from the paraffin until the 
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tissue was reached.  Switching to 5 µm, a ribbon with the complete tissue section was 
obtained and carefully laid on a hot water bath.  The ribbon would be scooped up with a 
microscope slide and dried overnight in an oven.  The slides are now ready for staining. 
3.2.4 H&E Staining 
 Slides with tissue sections were deparaffinized and stained using hematoxylin and 
eosin.  The hematoxylin stains the nuclei of cells blue and the eosin stains the ECM 
proteins various shades of red, pink, and orange.  After staining, the sections were imaged 
using an inverted Zeiss Axiovert light microscope and associated AxioVision software.  
Images were taken at 10x, 20x, and 40x magnification. 
3.2.5 DAPI Staining 
 Slides with tissue sections were deparaffinized and a drop of DAPI was added to 
the slide.  All slides were incubated at 4ºC for 20-30 minutes.  The DAPI stains cell 
nuclei a luminescent blue detected using the Zeiss Axiovert fluorescent microscope and 
associated AxioVision software.  Images were taken at 10x, 20x, and 40x magnification. 
3.2.6 Agarose Gel Electrophoresis 
 A 10x TBE buffer solution made up of TRIS, Boric Acid, EDTA, and ddH2O at a 
pH of 8.3.  A 0.5x TBE buffer solution was mixed with agarose to produce a 1% agarose 
gel solution.  The rest of the TBE buffer was diluted to make the electrode buffer.  In 
order to make the gel, the agarose gel solution was heated in a microwave for 1 and a half 
minutes pausing every 30 seconds to stir the solution.  After heating, 5 µL of ethidium 
bromide was added to the mixture.  The gel mixture was allowed to cool to 60ºC before 
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pouring into the mold and combs were appropriately placed.  Upon solidification, the 
combs were removed from the gel to expose the wells.   
For sample preparation, 4 µL of loading dye was added to 16 µL of sample.  To 
prepare the standards, 2 µL of DNA ladder was added to 4 µL of loading dye and 14 µL 
of ddH2O.  The samples and standards were spun down and 20 µL was added to each 
well.  The mold with samples were placed into the electrophoresis module and filled with 
TBE buffer.  Electrophoresis was run at 100V for 60 minutes.  The gel was imaged using 
BioRad ChemiDoc™ MP System and the bands were analyzed for relative intensity 
using the accompanying imaging software. 
3.2.7 Live-Dead Assay 
 As described in section 2.2.12, a live-dead assay was used to check cell viability 
on the arterial scaffolds after the bioreactor study. 
3.3 Hypertension Model using Specialized Vascular Chambers 
3.3.1 hSMC Seeding onto Decellularized Porcine Carotid Arteries 
 Vascular seeding chambers developed by Dr. Lee Sierad and Dr. James Chow, 
previous graduate students, were used to hold the porcine carotid arteries in place and to 
seed cells into the lumen.  All materials were sterilized using steam or ethylene oxide 
treatment before handling the arteries; a list of all the materials and the corresponding 
sterilization technique used is listed in Table 9 below. 
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Material Sterilization Technique 
1 Large Forcep Autoclaved 
2 Small-Medium 
Forceps Autoclaved 
2 Scissors Autoclaved 
12 male luer caps Autoclaved 
4-6 male 1/4" luers Autoclaved 
4-6 male 1/8" luers Autoclaved 
4-8 zip ties Autoclaved 
12 bolts Autoclaved 
12 nuts Autoclaved 
12 washers Autoclaved 
4 silicone membranes EtOH 
4 membrane clamps EtOH 
2 holding chambers EtOH 
1 sterile syringe Pre-packaged sterile 
1 sterile needle Pre-packaged sterile 
4 petri dishes Pre-packaged sterile 
1-3 sterile fields Pre-packaged sterile 
2 sterile sleeves Pre-packaged sterile 
1-2 pairs of sterile 
gloves Pre-packaged sterile 
1 sterile T75 flask Pre-packaged sterile 
Table 9. List of materials and sterility technique 
Inside of the biosafety cabinet, the media bottle containing the sterile arteries in 1X PBS 
and antibiotic/antimycotic was brought into the biosafety cabinet and the cap was 
removed.  The T75 flask was filled with about 100 mL of media and left uncapped beside 
the 1X PBS.  Using the large sterile forcep, sterile arteries were transferred from the 
media bottle to the T75 flask containing SMC media.  The arteries were pre-conditioned 
in SMC media overnight inside of an incubator at 37ºC. 
 On the following day, a sterile field was set-up inside of the biosafety cabinet.  
All of the sterilized materials found in Table 9 were opened and dumped onto the sterile 
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field without breaching sterility.  The T75 flask containing the arteries was placed inside 
of the biosafety cabinet beside the sterile field and was left uncapped.  Two sterile sleeves 
were opened and dumped onto the sterile field.  Once everything was prepared, sterile 
gloves were put over the regular nitrile gloves inside of the hood.  Using sterile forceps, 
two arteries were retrieved from the T75 flask and placed into one of the petri dishes.  
The ends of each artery were fashioned with either a 1/4” or 1/8” male luer depending on 
the inner diameter of the arteries.  Zip-ties were used to ensure that the arteries were 
firmly attached to the male luers.  The male luers at each end of the artery were carefully 
twisted into the holding chamber and inspected to ensure that there were no kinks or 
twists that could negatively influence fluid flow.  Silicone membranes and corresponding 
membrane clamps were bolted onto each open side of the holding chamber.  The arteries 
were now ready for cell seeding. 
 SMCs were detached using trypsin/EDTA, spun down, re-suspended in 2 mL of 
media, and counted using the techniques described in section 2.2.3.  About 6 million 
SMCs were injected into each artery and another 4 mL was used to completely fill the 
lumen of each artery based off of each artery’s inner surface area.  The openings at the 
ends of each seeding chamber were capped.  Both seeding chambers were transferred 
from the biosafety cabinet to the incubator set at 37ºC and 5% CO2.  In 15-minute 
increments, the seeding chambers were rotated to a different side to make sure the cells 
would evenly adhere throughout the lumen of the artery.  After a 2-hour rotation period, 
the chambers were left overnight in the incubator to ensure cell adhesion. The final 
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seeding chamber set-up including cell media and arteries with can be seen in Figure 36 
below. 
 
Figure 36. Seeding chamber containing decellularized porcine carotid arteries re-seeded with hSMCs 
submerged in cell media 
3.3.2 Bioreactor Set-Up – Hypertension Pathology Model 
 The initial bioreactor set-up was designed under non-sterile conditions using 
water and tubing as seen in Figure 37 below. 
 
Figure 37. Initial Bioreactor Set-Up in Non-Sterile Conditions 
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Changes were made to this first iteration of the pathology model.  Using Poiseuille’s 
equation for volumetric flow rate seen in Figure 38 and experimental pressure readings, 
the tubing length between the media bottle and the first manifold was optimized to ensure 
that a luminal pressure of 140 mmHg would be experienced inside of each arterial 
scaffold.   
 
Figure 38. Poiseuille’s equation relating volumetric flow rate and pressure14 
Initially, the pinch valve was implemented to the bioreactor system to mimic one cardiac 
cycle; the valve was set to close for 0.53 seconds for diastole and open for 0.27 seconds 
for systole.  However, the pinch valve could not overcome the pressure profile sustained 
by the peristaltic pump, so the pinch valve was removed from the system.  Instead, the 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
14 Image taken from http://hyperphysics.phy-astr.gsu.edu/hbase/ppois.html 
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length and diameter of the tubing was manipulated to obtain the ideal pressure profile for 
the pathology model.  In the end, 5 cm of the 3/4” PVC tubing was connected to 50 cm of 
the masterflex tubing, which was then connected to 5 cm of the 1/4” PVC tubing that 
attached to the first manifold.  This produced a hypertensive pressure profile similar to 
the normotensive pressure profile of a healthy femoral artery within the body as seen in 
Figure 39 and Figure 40.  Additionally, the 1/8” PVC tubing connecting the 1/4” 
masterflex tubing was exchanged for a 1/4” PVC tubing because the 1/8” tubing was 
prone to leaking.  Most of these changes can be seen in Figure 41.  Note that two 
manifolds would be implemented in the final model in order to fit both seeding chambers 
and two pressure sensors would be incorporated on the first manifold right before the 
fluid entered in order to generate an accurate pressure profile on LabView®.  
 
 
Figure 39. Physiological Pressure Profile for Various Arteries15 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
15 Image taken from Guyton, A. C., & Hall, J. E. (2000). Textbook of medical physiology. Philadelphia: Saunders.  
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Figure 40. Hypertensive Pressure Profile within Bioreactor System Displayed on LabView® 
 
Figure 41. Second Iteration of Model Design Inside of Incubator 
After configuring the bioreactor system to have optimum settings, additional bioreactor 
components and the technique used to sterilize them are listed in Table 9. 	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Material Sterilization Technique 
2 1/8" PVC tubing (length: 10 cm each) Autoclaved 
2 1/4" PVC tubing (length: 20 cm each) Autoclaved 
2 1/4" PVC tubing (length: 2 cm each) Autoclaved 
1 1/4" PVC tubing (length: 30 cm) Autoclaved 
2 3/4" PVC tubing (length: 5 cm each) Autoclaved 
1 1/4" masterflex tubing (length: 50 cm) Autoclaved 
2 1/4" to 3/4" luer connectors Autoclaved 
1 1/4" to 1/4" luer connector Autoclaved 
10 1/4" male luers Autoclaved 
4 1/8" male luers Autoclaved 
Male luer caps Autoclaved 
1 media bottle with 3/4" tubing attachments Autoclaved 
2 manifolds EtOH 
1 media bottle cap Pre-packaged sterile 
2 pressure sensors Pre-packaged sterile 
Table 10. List of additional bioreactor materials and corresponding sterilization technique 
A new sterile field was set-up inside of the biosafety cabinet.  All of the materials listed 
in Table 10 were placed onto the sterile field without breaching the sterility of the items 
or the field.  Next, the two seeding chambers were placed inside of the hood beside the 
sterile field.  Sterile glove and sterile sleeves were applied and the final bioreactor system 
was set-up.  When the assembly was complete, 300 mL of SMC media was added to the 
media bottle and the bottle was capped.  The system was transferred to the incubator and 
attached to a peristaltic pump, which generated a constant flow rate of 150 mL/min.  The 
final bioreactor set-up is displayed in Figure 41. 
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Figure 42. Complete Seeding-Bioreactor Chamber Set-Up 
The decellularized porcine carotid arteries re-seeded with hSMCs were subjected to a 
physiological flow rate of 150 mL/min and an elevated luminal pressure of 140 mmHg, 
which are conditions that emulate the natural flow rate and pressure profile of the femoral 
artery within the body.  The bioreactor ran for a total of two days and the artery cross-
sections were examined using a Live-Dead Assay and H&E staining to check for cell 
viability and adhesion as well as ECM integrity. 
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3.4 Results 
3.4.1 DAPI Staining 
 
Figure 43. DAPI Images Comparing Fresh and Decellularized Arteries 
3.4.2 Agarose Gel Electrophoresis 
 
Figure 44. DNA Gel Electrophoresis Comparing Fresh and Decellularized Arteries 
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3.4.3 Preliminary Results from Bioreactor Study 
 
Figure 45. Live-Dead Stain of Arteries in Preliminary Bioreactor Study 
 
Figure 46. H&E Stain of Arteries in Preliminary Bioreactor Study 
3.5 Discussion  
From the DAPI images in Figure 43, there were no residual cells on the 
decellularized arteries compared to the fresh arteries, which displayed fluorescent blue 
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nuclei of cells across all of the layers on the arterial wall.  Additionally, Figure 44 shows 
that the DNA content for the decellularized porcine carotid arteries were non-existant, but 
distinct bands indicative of DNA content were seen on the fresh arteries and matched the 
bands found on the ladder.  Overall, sodium hydroxide (NaOH) decellularization of the 
porcine carotid arteries was successful.  If these arteries were to be implanted into 
patients, there would not be an immunogenic response, which is a highly coveted 
characteristic when designing tissue-engineered blood vessels (TEBVs). 
Through several design iterations, a pathology model for studying hypertension 
was successfully created by adapting seeding chambers developed by Dr. Lee Sierad and 
Dr. James Chow into a bioreactor system, which is portrayed in Figure 42.  By doing 
this, seeding cells onto decellularized arteries and TEBV conditioning could be 
streamlined within one module.  Future bioreactor designs could even incorporate 
perfusion decellularization of fresh porcine carotid arteries within the same chamber.  
Thus, xenogenic artery decellularization, scaffold re-cellularization, and TEBV 
conditioning could all take place in one detachable and portable chamber.  The 
hypertension pathology model was based off of the luminal flow rate of 150 mL/min, 
which is the typical flow rate experienced by the femoral artery within the body.  
Furthermore, the pressure waveform generated in the bioreactor system relatively 
matched the pressure profile of the femoral artery found in literature except the peak 
systolic pressure and peak diastolic pressure was elevated to 140 mmHg and 90 mmHg, 
respectively, to mimic hypertension.  Live-Dead and H&E images found in Figure 45 
and Figure 46, respectively, showed that cells were able to adhere to the lumen of the 
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artery scaffolds and that the ECM remained intact demonstrating that the arteries could 
withstand the elevated blood pressure levels induced in the bioreactor system.  Despite 
these initial successes, the pathology model needs to be optimized for future studies. 
From a design standpoint, assembling the chambers that hold the artery scaffolds 
proved to be cumbersome and leaking occurred at the interface between the silicone 
membranes and the holding chamber.  Moreover, the nuts and bolts were difficult to 
tighten because there was not a tool that could be sterilized or could fit nicely over the 
nuts because the bolts were two long.  A two-piece design with a locking mechanism 
could solve these design issues.  Although cell viability and adhesion can be seen in both 
the Live-Dead and H&E stains found in Figure 45 and Figure 46, there were more dead 
cells than live cells and not enough cells adhered throughout the luminal surface of the 
entire artery.  Additionally, the hSMCs used in this study were injected directly into the 
lumen of the decellularized scaffold, which is anatomically incorrect.  Future studies 
should include hSMCs injected into the media layer of the arterial scaffold and hECs 
seeded onto the intima.  Also, Masson’s trichrome staining and mechanical tests should 
be incorporated to fully characterize ECM integrity before and after the bioreactor study.  
Furthermore, optimization of cell seeding techniques should be a priority before 
conducting future studies with this hypertension model because there is no way to tell if 
the cells are dying because of elevated blood pressure levels or because of inadequate cell 
seeding.  For example, these vascular chambers could be incorporated into a system that 
implements rotational dynamic seeding, which would drastically improve cell distribution 
and attachment on the scaffold.   
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Overcoming these current challenges will yield a pathology model that can be 
used to study the effects of hypertension on cell adhesion and vasoregulation and can be 
modified to study other vascular diseases.  Additionally, this innovative system could be 
tailored to develop functional TEBVs for clinical use in patients with these vascular 
diseases. 
3.6 Conclusion 
 An innovative bioreactor system was successfully developed as a pathology 
model for studying how hypertension causes endothelial injury and adverse arterial wall 
remodeling.  From the design process and preliminary studies, it was proven that unique 
vascular chambers could be used for xenogenic artery decellularization, recellularization 
of scaffolds, and TEBV conditioning.  However, the model needs to be optimized for 
future studies where cell viability and adhesion on decellularized scaffolds needs to be 
enhanced.  Despite these challenges, the versatility of this tissue engineering system can 
be used to study different vascular pathologies as well as develop clinically relevant 
TEBVs in the future. 
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Chapter 4: Conclusive Remarks and Future Directions 
 Hypertension is a unique disease that can either precede other vascular diseases as 
a risk factor or directly stem from pre-existing vascular diseases, so fully understanding 
the pathophysiology behind hypertension would be beneficial for patients with a 
spectrum of vascular diseases.  As established in this thesis, the FlexCell® system and 
bioreactor are excellent platforms for investigating every aspect of hypertension and 
other vascular diseases.  More pathology models like the two in this thesis should be 
developed and utilized because holistically understanding the disease process will lead to 
better detection and treatment paradigms for diseases like hypertension.  
 Despite promising results discovered in this thesis, more modifications to the 
bioreactor pathology model are necessitated.  With regards to the vascular chamber, 
future design iterations should look into preventing leaks and improving the locking 
mechanism.  Seeding techniques are continuously being refined and optimal seeding of 
hSMCs and hECs onto vascular scaffolds is attainable in the near future; for example, 
rotational dynamic seeding would improve the attachment and distribution of cells along 
the vascular scaffold.  After achieving an ideal bioreactor system for studying various 
vascular pathologies, the transition to developing clinically relevant TEBVs with the 
same bioreactor system is warranted.  Lastly, the tissue-engineering paradigm has solely 
focused on reseeding scaffolds with cells and bioreactor conditioning.  The incorporation 
of a pharmacological aspect to the foundational tissue-engineering paradigm could yield 
better TEBVs by enhancing cell attachment and viability during the re-seeding process or 
by improving TEBV mechanical properties.  Thus, the union between pharmacology and 
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tissue-engineering is a necessary step in progressing the field.  Although great strides 
have been made in the field of vascular tissue engineering, there is a lot of research 
remaining before a suitable TEBV can be implanted in patients with vascular disease. 
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